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1 Background 
1.1 The Communication 
The policy priorities of the European Commission regarding HIV in Europe are contained in a Communication 
entitled Combating HIV/AIDS in the European Union and neighbouring countries, 2009–2013.1
• To reduce new HIV infections across all European countries by 2013 
 The main objectives 
are: 
• To improve access to prevention, treatment, care and support 
• To improve the quality of life of people living with, affected by or most vulnerable to HIV/AIDS in the 
European Union and neighbouring countries. 
The Communication highlights key elements of the response to HIV including political leadership, involvement of 
civil society and people living with HIV, wider society responsibilities, and universal access to prevention, treatment, 
care and support. It also highlights priority regions and priority groups and emphasises the improvement of 
knowledge, including surveillance, monitoring, evaluation and research. 
1.2 The Action Plan 
Details of around 50 actions intended to implement the Communication are included in an accompanying Action 
Plan. This plan is structured around six thematic issues: 
• Politics, policies and involvement of civil society, wider society and stakeholders 
• Prevention 
• Priority regions 
• Priority groups 
• Improving knowledge 
• Monitoring and evaluation. 
1.3 Building on the previous Communication 
The Communication and Action Plan build on previous documents for the period 2006–2009. The current 
documents were introduced following an Impact Assessment2
1.4 Monitoring the Communication and Action Plan 
 of work carried out under the previous 
Communication and Action Plan. The Impact Assessment described the organisations, stakeholders and funding 
modalities which had enabled the activities outlined in the first Action Plan to be realised. The Impact Assessment 
highlighted progress and achievements in terms of EU policies, health and research programme actions and, in 
particular, the success of the Action Plan in ‘increasing the political commitment of European leaders to keep 
HIV/AIDS on their agenda and empowering civil society in the European Union’. It also highlighted the need to fully 
realise political commitments; improve the effectiveness and targeting of prevention strategies and access to 
treatment; strengthen surveillance; ensure comprehensive reporting of data and address knowledge gaps, and 
enhance action on neighbourhood policies.  
The Communication, Action Plan and Impact Assessment all express a clear commitment to monitoring and 
evaluating the implementation and effects of the activities outlined in the Communication and Action Plan. One 
challenge faced by the Impact Assessment was that there was no clear and systemic approach to monitoring and 
evaluating the previous Communication and Action Plan. As a result, it was only possible to describe activities 
rather than to conduct a more rigorous assessment of results achieved. In February 2010, the European 
Commission asked the European Centre for Disease Prevention and Control (ECDC) to develop a monitoring and 
evaluation framework for the current Communication and Action Plan.  
  
 
                                                                    
1 Commission of the European Communities. Communication from the Commission to the European Parliament, the Council, the 
European Economic and Social Committee and the Committee of the Regions. Combating HIV/AIDS in the European Union and 
neighbouring countries, 2009–2013. COM(2009)569. Brussels, 26 October 2009. 
2 Commission of the European Communities. Impact Assessment. Accompanying document to the Communication. 
SEC(2009)1404/2. Brussels. 
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1.5 The monitoring and evaluation framework 
Through a process of consultation with stakeholders, including the Commission, the Think Tank and the Civil 
Society Forum, ECDC developed a framework for monitoring and evaluating the Communication and Action Plan 
(see Figure 1.1). The focus of the framework is on monitoring the added value of European-wide and Commission 
actions in responses to HIV in the region. It does not seek to capture all actions by all those working to combat 
HIV in Europe. Rather, it aims to capture the activities of a range of actors, including countries, Commission 
agencies and services, international agencies and civil society organisations, which result from Commission policies, 
influence, funding and other actions. 
The framework is based on a ‘theory of change’ which illustrates how the Communication and Action Plan are 
expected to contribute to achieving the Commission’s objectives. This assumes that certain financial and non-
financial inputs made available to different actors to support the implementation of the Communication and Action 
Plan will contribute to certain results. This flow is illustrated by a black arrow at the top of Figure 1.1. Financial 
inputs in a variety of forms are shown as blue boxes and non-financial inputs are shown as yellow boxes. The 
results, shown as white clouds, contribute to the ultimate objectives of the Communication and Action Plan, shown 
as blue clouds. Inputs and results are also mapped against the main thematic issues of the Communication and 
Action Plan, shown in blue on the left of Figure 1.1. 
 
 
 
 
 
Figure 1.1: Framework for monitoring the HIV Communication and Action Plan 
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1.6 Using the framework to monitor the Communication and 
Action Plan 
ECDC is supporting efforts to monitor the implementation of the Communication and Action Plan using this 
framework in two ways. 
Ongoing efforts to monitor progress on implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS 
in Europe and Central Asia are expected to produce definitive information on the results being achieved by country 
responses to HIV. 
New efforts, documented in this report, to monitor inputs directly related to the Communication and Action Plan 
and their effect should indicate how the Plan is contributing to the European region’s response to HIV. 
Activities related to the first process will be published in a report at the end of 2012. This interim report focuses on 
the second process. A final report on the contribution of the Communication and Action Plan will be published in 
2013. This will explore links between the results of the Communication and Action Plan and those measured by 
monitoring the Dublin Declaration.  
ECDC developed a series of indicators and related questions intended to collect information on each element of the 
monitoring and evaluation framework. Each question was directed to one or more organisations. Relevant 
questions were set out in a questionnaire tailored to each organisation and these were completed between June 
and September 2011. Questionnaires were sent to the European Commission including some of its Delegations, the 
Civil Society Forum, members of the Think Tank, ECDC, EMCDDA, EAHC, UNAIDS and WHO Regional Office for 
Europe. Responses were received from: 
• The European Commission, including a specific response from the Directorate-General for Research and 
Innovation 
• Delegations in Belarus, Moldova, Russia and Ukraine 
• The Civil Society Forum – the CSF coordination team submitted a consolidated response based on replies 
from 14 members3
• Think Tank members from Bulgaria, Denmark, Germany, Moldova, the Netherlands, Norway, Poland, 
Portugal, Russia, Slovakia, Spain, Sweden and Ukraine 
 
• ECDC 
• EMCDDA 
• EAHC 
• NDPHS 
• UNAIDS. 
As part of the analysis, follow-up discussions were held with the Commission, EAHC and ECDC and the NDPHS to 
clarify responses and collect additional data.  
1.7 Report structure 
This report summarises the data collected and presents it on the basis of the framework. Each section of the report 
starts with a diagram of the framework highlighting the part covered in that section. 
Section 2 describes the financial inputs available for the implementation of the Communication and Action Plan 
Section 3 describes the non-financial inputs available for the implementation of the Communication and Action Plan 
Section 4 considers the effects of these inputs and their contribution towards achieving the results envisaged in the 
Communication and Action Plan. 
Section 5 sets out key conclusions and recommendations. 
  
 
                                                                    
3 Sensoa, Belgium; TAMPEP International Foundation, Regional; Swiss AIDS Federation, Switzerland; HIV Nordic, Finland; LILA,  
Italian League For Fighting AIDS,  Italy; Soros Foundation, Moldova; AIDS Hilfe Wien, Austria; Dia+Logs, Latvia; All-Ukrainian 
Network of PLWH, Ukraine; Odyseus, Slovakia; Deutsche Aids Hilfe, Germany; Projecte dels NOMS-Hispanosida; HIV Denmark. In 
addition, a later response from GAT, Portugal was included. 
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2 Financial inputs 
This section focuses on the financial inputs (highlighted by a red box in Figure 2.1) available for implementation of 
the Communication and Action Plan. As there is no specific financial allocation for this, it draws on information from 
a number of sources which are discussed here (see Figure 2.1). Approximate annual values from each of these 
sources are summarised at the end of this section in Table 2.1. 
Figure 2.1: Framework for monitoring the HIV Communication and Action Plan: Financial inputs  
 
2.1 Funding to countries 
The Global Fund to Fight AIDS, Tuberculosis and Malaria has provided significant financing to counteract HIV in 
European countries4
The European Commission has been a major contributor to the Global Fund. From 2002–2011, the Commission 
reports that it provided the Global Fund with EUR 1.2 billion, which makes it the Fund’s sixth largest donor after 
the United States, France, Germany, the UK and Japan. According to figures from the Global Fund, since its 
formation 6.2% of the Fund’s total finances have been provided by the European Commission. This means that of 
the USD 731 million disbursed to the region by the Global Fund during that period, USD 45 million (6.2%) 
effectively originated from the European Commission. 
 since its establishment in 2002. During the period 2002–2011, the Global Fund approved the 
provision of USD 972 million as grants in response to HIV in the region. By 2011, a total of USD 731 million had 
been disbursed. 
The USD 45 million provided by the Commission5
  
 for national responses to HIV in EU and ENP countries and the 
Russian Federation benefited 18 countries, with the largest amounts going to the Russian Federation and Ukraine 
(see Figure 2.2). Some examples of programmes provided through this financing are given in Box 2.1. 
 
                                                                    
4 For the purpose of this analysis, European countries include those countries coming within the Global Fund’s Europe and 
Central Asia region which are either EU Member States, European Neighbourhood Policy (ENP) countries or countries with which 
the European Union has a partnership and cooperation agreement (the Russian Federation). 
5 An estimated, pro rata, annual amount provided by the Commission through the Global Fund is included in Table 1, Section 2.5 
Funding, e.g. through 
Global Fund; 
instruments  available 
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Candidate Countries; 
instruments available to 
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Figure 2.2: Estimated pro rata amounts of funding provided by the European Commission as a 
response to HIV in EU and ENP countries and the Russian Federation through the Global Fund: 2002–
2011 
 
 
Box 2.1 Examples of country programmes supported by Global Fund financing 
Belarus has received two Global Fund grants worth a total of USD 38.4 million for its national HIV response. The 
first grant, which runs from 2012–2014, focuses on promoting prevention and treatment of HIV and AIDS. The 
programme is seeking to boost HIV prevention among injecting drug users (IDUs), men who have sex with men 
(MSM), women who sell sex, prisoners and young people. In addition, the programme seeks to ensure adequate 
treatment, care and support for people living with HIV. The second grant, which runs from 2010 to 2016, focuses 
on promoting universal access to HIV prevention, treatment and care for key affected populations.  
Moldova receives Global Fund support for a project entitled ‘Scaling-up access to prevention, treatment and care 
under the national program for prevention and control of HIV/AIDS/STIs 2006–2010 and reducing morbidity, 
mortality and HIV-related impact on people living with HIV/AIDS, 2010–2014’. 
The European Commission’s financial support to the Global Fund is part of a broader programme entitled Investing 
in People  under the Commission’s Development Cooperation Instrument. Investing in People has four main areas 
of focus – health, education, gender equality and other aspects of human and social development.6,7 The focus on 
health includes confronting the main communicable,8
In addition to the Commission’s support for the Global Fund, Investing in People has established a EUR 9 million 
programme to build up the capacity of non-state actors in the area of HIV/AIDS prevention, treatment and care for 
the European Neighbourhood and Partnership (ENP) countries.  
 neglected and emerging diseases.  
This programme specifically cites the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central 
Asia and the Commission Communication on Combating HIV/AIDS in the European Union and Neighbouring 
Countries 2009-2013. Procurement for this programme is ongoing, having begun in September 2010. The 
programme will cover seven countries.9
 
                                                                    
6 See European Commission (2010) 2010 Part 2 Action Programme covered by the 2007-2013 Strategy Paper for the Thematic 
Programme ‘Investing in People’ under the Development Cooperation Instrument 
 Grants are available to non-state actors focusing on at least two of the 
following areas: 
 
7 Several of these funding areas, e.g. education, are related to and will have indirect effects on HIV. 
8 HIV, TB and malaria are mentioned specifically. 
9 Armenia, Azerbaijan, Belarus, Georgia, Moldova, Ukraine and the Russian Federation. 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
U
SD
 m
 
 
 
 
 
SPECIAL REPORT Monitoring implementation of the Commission Communication and Action Plan on HIV/AIDS 
 
 
 
7 
 
 
 
• Strengthening advocacy skills of non-state actors 
• Enhancing the quality of service provided by non-state actors and the public sector 
• Strengthening partnerships and coordination among non-state actors and with public bodies 
• HIV prevention focused on adolescent and key populations at most risk and support, treatment and care for 
people living with HIV. 
 
In addition, it appears that funds from other areas of the Investing in People programme are being used to support 
national HIV responses, although this is not being tracked systematically. For example, at the Civil Society Forum 
in December 2011, a representative of Romanian civil society reported that such funds were being used to finance 
HIV prevention activities by Romanian NGOs that had previously been funded through a Global Fund grant. 
Another of the thematic programmes under the Commission’s Development Cooperation Instrument focuses on 
non-state actors and local authorities. Within this programme funding is available to support non-state actors in 
ENP countries and Russia, including EUR 2.15 million in Belarus, EUR 2 million in Russia, EUR 650 000 in Ukraine 
and EUR 250 000 in Moldova. 
Theoretically, structural funds are available for countries to use in their responses to HIV. However, it is unclear if 
any structural funds have been used directly in relation to HIV. 
Similarly, funding through the European Neighbourhood and Partnership Instrument (ENPI)10 can be used to 
finance responses to HIV. Some examples are given in Box 2.2. ENPI is the main financial mechanism through 
which assistance is given to European Neighbourhood and Partnership countries and Russia. Almost EUR 12 billion 
has been allocated to ENPI for 2007–2013. Priorities for ENPI funding include transport; energy; sustainable 
management of natural resources; border and migration management, the fight against transnational organised 
crime and customs; people-to-people activities and landmines, explosive remnants of war, small arms and light 
weapons. In 2011, ENPI also announced funding of EUR 22 million for a new civil society facility.11
 
. 
2.2 Funding to agencies of the European Union 
Executive Agency for Health and Consumers (EAHC) 
The European Health Programme organised by the EHAC includes a focus on supporting responses to HIV in line 
with the Commission’s Communication on HIV/AIDS.12
In 2009–10,  the programme allocated a total of EUR 6.1 million to HIV-related activities across a range of different 
thematic areas. Based on reports from EHAC, almost two thirds (62%) of funds allocated in 2009/10 focused on 
 The programme allocates funds through its annual work 
plan to a range of activities including conferences, operating grants and projects.  
 
                                                                    
10 See http://www.enpi-info.eu/main.php?id_type=2&id=359  
11 See http://www.enpi-info.eu/eastportal/news/latest/26632/%E2%82%AC22-million-for-new-Civil-Society-Facility-as-EU-steps-
up-Neighbourhood-response  
12 Executive Agency for Health and Consumers (2011) ‘Joining Together to Tackle HIV/AIDS in Europe’ 
Box 2.2: Examples of HIV and health-related activities supported in country through ENPI  
ENPI 2008 includes EUR 46.6 million for the health sector support programme in Moldova. The aim of this 
programme is to improve the health of the population and improve access to and the efficiency and quality of 
essential public health services. 
In Russia, the delegation has used ENPI funds to support projects in the social sector tackling HIV. For 
example, the Commission supported a project entitled ‘We Choose a Life – Youth Against HIV/AIDS’. This 
project was managed by the Baltic Region Healthy Cities Association from 2008 to 2010 and operated in four 
Russian cities – Cherepovets, Dimitrovgrad, Izhevsk and Stavropol. It was part of the Commission’s institution 
building partnership programmes (IBPP) aimed at giving active support to civil society organisations in Russia.  
In addition, the Commission uses ENPI to support an EU Baltic Sea Strategy External Action Programme, 
valued at EUR 20 million. As part of this programme, in 2011, the Commission launched a call for proposals 
directed at non-state actors and local authorities in the Baltic Sea region. This EUR 3.5 million grant scheme 
aims to support cooperation between the EU and Russia by encouraging local stakeholders to address common 
challenges and opportunities more effectively. One of the priorities of this scheme is to reduce the spread of 
communicable diseases, including HIV. 
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key populations at increased risk of HIV transmission, including people who inject drugs, men who have sex with 
men, sex workers, migrants, ethnic minorities and prisoners (see Figures 2.3 and 2.4).  
In addition, some of the programme’s funding for conferences to promote stronger leadership on HIV also focused 
on key populations, such as the International Harm Reduction Association’s conference in Liverpool, May 2010 and 
the Future of European Prevention among MSM (FEMP) in Stockholm, November 2011. 
Figure 2.3: Percentage of European Health Programme HIV funding allocated to different topics: 
2009/2010 
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Figure 2.4: Activities supported by European Health Programme HIV funding: 2009/2010 
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European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
EMCDDA is financed largely through a general subsidy from the European Community.13
European Centre for Disease Prevention and Control (ECDC) 
 In 2010, the EMCDDA 
budget was almost EUR 16 million. EMCDDA reports that its budget does not contain funds earmarked specifically 
for HIV and, therefore the Agency is not able to provide figures for the amount of funds used to promote the 
Commission’s Communication and Action Plan. Instead, EMCDDA reports that HIV-related activities are included in 
the overall budget for the scientific work of EMCDDA. EMCDDA HIV-related activities are discussed further in 
Section 4 of this report.  
ECDC reports that in the three years from 2009-2011, its estimated budget allocation for HIV projects was EUR 
2 267 698. These figures do not include staff time spent on HIV-related activities14
Figure 2.5: Distribution of ECDC budgetary allocations by type of HIV/AIDS project 2009–2011 
 or support functions (e.g. 
facilities, publications, administrative and financial activities or library staff. Figure 2.5 shows the relative allocation 
of funding to different types of HIV/AIDS projects over this three-year period, with 41% allocated to 
epidemiological and behavioural surveillance, 30% to evidence-based policies, 19% to monitoring and evaluation, 6% 
to scientific advice and 4% to coordination and communication. Figure 2.6 briefly summarises the types of 
activities funded by ECDC in each of these areas. These activities and their effects are discussed in more detail in 
Section 4 of this report. 
 
  
 
                                                                    
13 In 2010, the budget contained some additional funding from other countries, such as Norway and Turkey (see 
http://www.emcdda.europa.eu/publications/searchresults?action=list&type=PUBLICATIONS&SERIES_PUB=w216) 
14 Approximately three full-time equivalents in 2011 
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Figure 2.6: HIV/AIDS activities supported by ECDC funds: 2009-2011 
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2.3 Funding to key international organisations 
In 2010, the Joint United Nations Programme on HIV/AIDS (UNAIDS) reported receiving EUR 400 000 from the 
European Health Programme to raise awareness of HIV and AIDS in Eastern Europe and to support the 
International AIDS Conference in Vienna in 2010, in particular by funding the participation of civil society 
representatives. In addition, UNAIDS reported that it received additional funding from the EuropeAid Cooperation 
Office (AIDCO) Development Cooperation Instrument for its work outside the European Union and in neighbouring 
countries. According to the UNAIDS report on its income for 2010,15 total contributions from the European 
Commission amounted to just under USD 1.5 million, which accounted for 0.6% of UNAIDS’ total income. This 
compares to a total of almost USD 150 million received directly from 14 EU Member States.16
In addition, the European Commission provides direct and indirect funding through a number of different funding 
schemes to WHO, the United Nations Office on Drugs and Crime (UNODC) and the United Nations Population Fund 
(UNFPA). For example, the European Health Programme is providing EUR 299 109 over two years to WHO to 
conduct a project aimed at scaling up access to high-quality harm reduction, treatment and care for injecting drug 
users in the European region. 
 
2.4 Research funding 
The Commission’s Communication contains a strong commitment to HIV-related research. The Commission has 
provided significant levels of funding for HIV-related research through its Research Framework Programmes (RFPs). 
These RFPs are the EU’s main instrument for funding research in Europe. They are intended to channel European 
research on HIV into projects ranging from basic science to pre-clinical and early clinical testing of new drugs and 
therapeutic approaches, microbicides and vaccine candidates, clinical management of HIV-infected individuals, 
better prevention and improved treatments.  
The Sixth Framework Programme (2002–2006) provided an EU contribution of EUR 123 million to 41 projects on 
HIV-related research and also contributed EUR 200 million in financing to the European and Developing Countries 
Clinical Trials Partnership (EDCTP).17
During the first five years of the Seventh Framework Programme (2007–2011) the total EU contribution to 17 HIV-
related research projects was more than EUR 82 million. Almost all of the research spending (94%) related to 
development of treatment, vaccines and microbicides (see Figures 2.7 and 2.8).  
 
Research projects on therapy included those seeking to develop new antiretrovirals as well as projects looking at 
how to improve treatment adherence and patient follow-up. A number of research projects also focus on 
promoting coordination and cooperation among researchers (see Figure 2.8). As part of the Seventh Framework 
Programme, there was a call for proposals relating to behavioural research in the health field. However, during the 
evaluation of proposals submitted, no projects addressing HIV were selected for funding. 
  
 
                                                                    
15 Details of total contributions for 2010 are available at: 
http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/20110331_2010DonorTotalContributionTables
.pdf  
16 These countries (by size of contribution) were Sweden, the Netherlands, United Kingdom, Finland, Denmark, Luxembourg, 
Belgium, Ireland, Germany, Spain, France, Portugal, Austria and Poland. 
17 Since 2003, EDCTP has supported 24 clinical trials on HIV at a total cost of EUR 102 million.  
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Figure 2.7: Distribution of HIV research spending through the Seventh Framework Programme 
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Figure 2.8: HIV-related research projects funded through the Seventh Framework Programme 
 
 
  
Seventh 
Framework 
Programme HIV-
related research 
funding 
Therapy 
• iNEF - looking at evaluating HIV 1 Nef as an 
antiretroviral drug target 
• HIV-ACE – looking at targeting particle assembly 
as the basis for a novel antiretroviral 
• PENTA-LABNET – a laboratory network to 
improve the range of products and clinical use of 
antiretrovirals in HIV-infected children 
• THINC – targeting co-factors required for HIV 
replication 
• HIVIND - generating evidence on promoting 
adherence and patient follow-up from ART rollout 
in India 
• CHAIN – coordinating research into antiretroviral 
resistance 
• Eurocoord – coordinating HIV-related cohort 
studies 
Vaccines 
• NGIN – looking at new ways of 
developing neutralising antibodies 
• EuroNeut41 – developing new 
vaccines to elicit neutralising 
antibodies to block entry of HIV 
into cell and mucosal sites and in 
blood 
• INYVAX – addressing common 
gaps and challenges in developing 
vaccines for poverty-related 
diseases 
• PHARVAT – harmonisation of 
adjuvant testing 
• CUT’HIVAC – innovative 
transcutaneous and mucosal 
needle-free vaccination methods 
Other 
• Support to EUCO-Net which 
aims to coordinate research 
activities and policies 
• Support to PRD College 
which seeks to train young 
African and European 
scientists to perform 
research on poverty-related 
and neglected diseases 
• HIVERA – focused on 
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research programmes 
Basic science 
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understanding the 
interaction between 
different poverty-related 
diseases 
Microbicides  
• CHAARM – developing combinations 
of microbicides that will be 
designed to be specifically targeted 
agents 
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2.5 Overall annual financial inputs to support the 
Communication and Action Plan 
Funding has targeted HIV prevention, increasing access to prevention, treatment, care and support, especially in 
priority regions and for priority groups, research, surveillance and monitoring and evaluation. Table 2.1 shows the 
approximate financing available on an annual basis to support the Commission’s Communication and Action Plan, 
based on information provided and discussed above. However, these figures should be treated with great caution. 
They are very approximate and underestimate the actual financial input because accurate information is not 
available for all funding sources, e.g. structural funds and certain costs, such as staffing, which were not covered 
in several of the responses. The figures include Commission financing for the activities of the Think Tank and Civil 
Society Forum at an approximate annual combined cost of EUR 150 000.18
Table 2.1: Approximate financing available on an annual basis to support Communication and Action 
Plan
  
19 
Source EUR million 
Funding to countries  
Pro rata Commission contribution to the region through Global Fund 3.9 
Investing in People programme to build capacity among non-state actors 1.4 
Structural funds no data 
European Neighbourhood Partnership Instrument no data 
  
Funding through agencies of the European Union  
EAHC Health Programme 3.1 
EMCDDA 0.0 
ECDC 0.8 
  
Funding to key international organisations  
UNAIDS 1.1 
Other UN bodies 0.2 
  
Research funding 16.4 
  
Other funding  
Think Tank and CSF 0.2 
  
Estimated total: 27.1 
  
 
                                                                    
18 The Commission also has two full-time professional staff working on HIV within DG SANCO in addition to support staff. Staff in 
other parts of the Commission also focus on HIV as part of their work. 
19 All figures are approximate and rounded to one decimal point. 
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3. Non-financial inputs  
This section focuses on the non-financial inputs that support the implementation of the Communication and Action 
Plan (highlighted by a red box in Figure 3.1). This includes activities through a number of mechanisms including 
the EU Presidencies, Commission Delegations, the Think Tank and Civil Society Forum, Commission engagement 
with other international organisations, national AIDS coordinators, Commission involvement in the Northern 
Dimension Partnership in Public Health and Social Well-being, Commission cooperation with the private sector and 
various mechanisms for cooperation between the Commission, neighbouring countries and the Russian Federation. 
Figure 3.1: Framework for monitoring the HIV Communication and Action Plan: Non-financial inputs  
 
3.1 EU Presidencies 
From the second half of 2009 to 2011, EU Presidencies were held by Sweden, Spain, Belgium, Hungary and 
Poland. These Presidencies gave high priority to health issues,20
 
                                                                    
20 Hungary, which assumed the Presidency in January 2011, identified a stronger Europe; growth, jobs and social inclusion, 
and global engagement as its priorities.  
 with Sweden and Spain specifically including an 
event focused on HIV (see Figure 3.2). Two major conferences were organised during this period, one on HIV 
testing and care in 2009 under the auspices of the Swedish Presidency and one on HIV and vulnerability under the 
Spanish Presidency in 2010 (see Box 3.1).   
 
 
 
 
SPECIAL REPORT Monitoring implementation of the Commission Communication and Action Plan on HIV/AIDS 
 
 
 
17 
 
 
 
 
Figure 3.2: Health priorities and HIV activities of EU Presidencies 2009–2011 
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Box 3.1: Major HIV-related conferences organised under EU Presidencies 
 
Under the auspices of the Swedish Presidency, the HIV in Europe Initiative organised a conference entitled 
‘Working Together for Optimal Testing and Earlier Care’ in Stockholm in November 2009. The conference, 
which was attended by more than 100 policy makers, health professionals and civil society representatives 
from 25 countries, addressed issues including late presentation and barriers to the uptake of HIV testing, HIV-
related stigma and the criminalisation of HIV transmission. The aim was to increase awareness among the 
public and policy makers of public health implications resulting from late presentation for care. The conference 
was also designed to provide an opportunity to share best practices on optimal testing and early care and 
develop creative solutions to improve early diagnosis and care. Important outcomes of the conference included 
significant progress towards a consensus on defining late presentation and a list of indicator diseases for HIV – 
the latter is important since many late presenters may have already been in contact with health services but 
not had their HIV status diagnosed. There was also a discussion of innovative ways in which to estimate the 
size of the infected-but-not-yet-diagnosed population in order to develop clear guidance for countries.  
Coinciding with the European Year for Combating Poverty and Social Exclusion, the Spanish Presidency 
identified HIV and health inequalities as a major priority and organised a conference entitled ‘Vulnerability and 
HIV in Europe’ in Madrid in April 2010. The conference was organised by the National AIDS Strategy 
Secretariat of Spain’s Directorate-General for Public Health and Foreign Health Affairs. It brought together 
representatives of organisations and networks from around the EU to share experiences and discuss 
inequalities, vulnerability to HIV and effective interventions and policies. It focused on key populations at 
higher risk such as men who have sex with men, people who use drugs, and migrants. The conference 
concluded that it was important to better address the needs of key populations, to offer comprehensive 
responses that incorporate social as well as biomedical approaches, and to improve second generation 
surveillance, early diagnosis of HIV, and HIV prevention. The conference was an important step towards 
greater EU cooperation and collaboration on programmes to reduce inequalities and factors that increase HIV 
vulnerability. Moreover, it also called for further action to enhance political leadership, commitment, and 
coordination of Member States to address the needs of most-at-risk populations through policies, legislative 
changes and support for sustainable and mainstreamed programmes. 
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3.2 EU Think Tank 
The EU’s Think Tank on HIV/AIDS, which meets twice a year, was established following the Dublin Conference in 
2004. The main purpose of establishing the Think Tank was to support the Commission in developing the first 
Communication and Action Plan 2006–2009. The Think Tank includes representatives from Member States, EEA 
and Candidate Countries. Relevant international and regional organisations and pan-European NGOs represented 
on the EU Civil Society Forum (CSF) are also invited to meetings.  
The Think Tank is a forum for exchange of information and coordination of the response to HIV and AIDS in the 
EU and neighbouring countries and serves as a venue for informal consultation between the Commission, Member 
States, EEA/EFTA, Candidate Countries and neighbouring countries. Figure 3.3 illustrates how the Think Tank, and 
the CSF, bring together national and regional perspectives and facilitate exchange on European-wide policy and 
action and national responses.  
Figure 3.3: Consultation, exchange of information and policy dialogue through the EU’s HIV/AIDS 
Think Tank  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An analysis of the topics covered at Think Tank meetings shows the diversity of issues and range of policy areas 
addressed. The May 2010 meeting discussed a rights-based approach to HIV in Europe; Global Fund replenishment 
and the impact of the economic crisis; HIV prevention in MSM and progress in monitoring the Dublin Declaration. 
The October 2010 meeting covered HIV in prisons; harm reduction among drug users in Spain; the HIV situation in 
the Russian Federation and WHO plans for improving the effectiveness of HIV prevention through quality 
assurance and quality improvement practices. The June 2011 meeting discussed NGO funding and the potential 
impact of the economic crisis on access to treatment, particularly in neighbouring countries; criminalisation of HIV 
transmission; prison health; updates on research initiatives and new guidelines, and discussion of possible joint 
action on HIV prevention.   
Questionnaire respondents report that the Think Tank plays an important role in defining priorities for the HIV 
response in the EU and neighbouring countries. It also provides an important forum for countries to discuss policy 
and technical issues, exchange information and experience and ensure that national responses are in line with the 
rest of Europe. Several respondents highlighted the value of the Think Tank in sharing ideas and experience on 
HIV prevention policies and programmes.  
‘The Think Tank is a solid platform to discuss successful approaches to prevention, service delivery for people 
living with HIV, and monitoring and evaluation’ – Think Tank member, Russian Federation. 
‘Meetings have discussed topics including risk groups, health systems strategies, universal access and 
improving HIV prevention’ – Think Tank member, Moldova. 
‘Regular updates on international and national developments and projects are an important component of 
Think Tank meetings… The resulting networking and exchange of policy and practice is a source of inspiration 
at national level’ – Think Tank member, the Netherlands. 
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To encourage a more intensive exchange of views on certain issues, the Commission has created a ‘country 
representative’ forum as part of the Think Tank agenda. This enables country representatives to meet without 
agency or CSF representatives. At the last session the focus was on HIV testing issues. 
The Think Tank facilitates dialogue and the flow of information between the Commission, Member States and 
neighbouring countries. For example, Think Tank members were consulted by the Commission to determine the 
effects of the current international financial crisis on national HIV responses (see Box 3.2). The Think Tank also 
enables country representatives to give feedback on Commission policies and strategies and provides the 
Commission with an opportunity to draw attention to emerging issues (e.g. migrants and prisons).  
‘The Think Tank is also useful for exchanging views on how to implement national policies. Meetings enable 
countries to share their perspectives and experience on a variety of medical, technical, scientific and legal 
issues’ – European Commission 
In addition, the Think Tank provides a forum for EU Presidencies to consult with country experts and seek 
information and advice.  
Through the Civil Society Forum, the Think Tank allows the perspectives of civil society to be heard and promotes 
interaction between government and civil society representatives. The Think Tank has promoted the prioritisation 
of HIV-related issues in EU policies, legislation and agreements. It has also added value to the policy development 
process at country level by facilitating dialogue between national authorities, civil society and international 
agencies.  
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Box 3.2: Commission questionnaire to Think Tank members on how the financial crisis is affecting 
national responses to HIV 
At the December 2011 Civil Society Forum and Think Tank meetings, the Commission reported on a questionnaire 
completed by Think Tank members on the effects of the global financial crisis on national HIV responses. The 
questionnaire consisted of eight questions and responses were provided on an anonymous basis. A total of nine 
countries responded to the questionnaire.  
Seven countries confirmed that the financial crisis had had an effect on the national HIV response while two 
reported that it had not. Those countries affected reported that they had had to prioritise key services. In specific 
countries, there had been: 
    Limitations on HIV testing 
    A reduction in the HIV prevention budget 
    Reduced HIV funding to NGOs 
    Postponement of plans to reach other key populations. 
Seven countries reported that there had been no change in the number of personnel working in HIV response, 
however two countries reported that there had been reductions. These included not replacing retiring staff and loss 
of NGO personnel as a result of reduced funding. Reduction in staff also involved limitations being placed on some 
services, e.g. a decrease in the number of public information campaigns and less staff training in one country. 
Four countries reported that budget cuts had had an effect on people living with HIV, including reductions in 
hospital budgeting and staffing levels; less availability of non-medical care for people living with HIV; and 
increasing difficulty for people living with HIV to afford out-of-pocket payments. One country reported that 15% of 
people living with HIV had given up care for financial reasons including worsening social environment, lack of 
health insurance and rising health costs. 
Only two countries reported that the social environment for people living with HIV had changed as result of the 
financial crisis and one of these reported that it had changed for the better. The country that reported a worsening 
social environment considered that this was largely due to rising unemployment. Only one country reported that 
the legal environment had changed with regard to illegal immigrants. However, this change was not necessarily 
considered to be related to the financial crisis. Eight countries reported that there had been no other policy effects 
and no impact on cooperation with other countries. One country reported that it was more difficult to attend 
international meetings. 
Countries identified a number of steps to be taken to address the impact on national HIV responses resulting from 
the financial crisis. These included: 
Legislative changes 
Increasing budgets and rebuilding activities 
Increasing collaboration among partners 
Greater harmonisation of activities 
Establishing a governmental body for HIV 
Auditing all projects 
Adopting a state target programme 
Defining the responsibilities of partners within the national HIV response. 
 
 
3.3 EU Civil Society Forum 
The Communication highlights the important role of civil society and of people living with HIV in combating HIV 
and AIDS and keeping the issue on the political agenda. The Civil Society Forum (CSF) was established by the 
Commission in 2005 to ensure civil society involvement in HIV policy development and in a coordinated response. 
The CSF, which meets twice a year, serves as the interface between European civil society, the Commission and 
the Think Tank, and plays a critical role in facilitating direct dialogue between civil society and policymakers. 
The CSF provided substantial input to the Commission’s Communication and Action Plan, helping to ensure that the 
final documents reflected the concerns of civil society. The CSF has used the Communication and Action Plan as a 
framework for meetings and for regional and national advocacy. Meetings and follow-up action have focused on 
issues such as HIV prevention, treatment and care for people who inject drugs, men who have sex with men and 
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prisoners, testing guidelines, drugs policies, human rights (see Box 3.3) discrimination in the workplace (see Box 
3.4), and funding for NGOs in Eastern Europe. 
 
The CSF is an important venue for sharing information and good practice, stimulating discussion, and developing 
recommendations and advice, both to improve the quality and impact of civil society programmes and to generate 
action at European and country level. In addition, it acts as a vital channel for information flow between the 
Commission and national civil society, and in disseminating information and material to CSF members.  
‘It has great added value because you can exchange and learn and take back to your country what works in 
other countries’ – CSF member, Portugal. 
‘…although the epidemic among IDU in the UK is small, we have learned a great deal about this from others 
which proved relevant in policy debates in the UK…’ – CSF member, UK 
‘I see the CSF as a very good source of information... I also share all the information in Finland at meetings 
and networks’ – CSF member, Finland. 
‘We were able to contribute to CSF meetings with presentations on Germany’s MSM prevention efforts and 
this was a great opportunity to get feedback from CSF members and to discuss approaches to the MSM 
community all over Europe’ – CSF member, Germany.  
 
 
The CSF is able to articulate the concerns of European civil society organisations at international and regional level. 
For example, at the Vienna Conference in 2010, the CSF co-chair was one of the keynote speakers at a 
Commission-supported satellite meeting on effective policies and measures in Europe to address key populations. 
The speech elaborated on how current legislation across the European region supports an effective and rights-
based response to the epidemic, drawing on the Communication and Action Plan, the ECDC Dublin Declaration 
report and the EU Charter of Fundamental Rights.  
The CSF also provides a forum for civil society to influence the policies and programmes of the Commission and 
international agencies, such as WHO and UNAIDS, and to reinforce the importance of civil society’s contribution to 
the HIV response at international, regional and national level.  
‘The CSF gives a voice and provides a coordination platform for European civil society, strengthening 
advocacy action and democratising decision-making at the European level’ – Think Tank member, Spain. 
The CSF provides input to the regional plans of international agencies such as UNAIDS and WHO and participates 
in international and regional advisory bodies. For example, the CSF co-chairs participate in the advisory groups 
convened by ECDC on HIV testing, infection control among IDU, and the monitoring of the Dublin Declaration. 
They also worked with ECDC on the development of a civil society questionnaire to monitor the Commission 
Communication and Action Plan. 
The CSF also plays an important role in advising EU Presidencies, the Commission and the Think Tank. For instance, 
it provided input for the Belgian EU Presidency representative’s speech to the Vienna Conference in 2010. A further 
example, at the October 2010 meeting of the Think Tank, saw CSF reporting on input received from Russian civil 
society. The CSF has also developed position papers, on drug policy for example, which are shared with the Think 
Box 3.4: ILO Recommendation 
In 2010, the CSF communicated the ILO Recommendation concerning HIV and AIDS and the world of work 
(No. 200) to its members, with suggestions of action they could take at country level to improve the situation 
for people with HIV in employment. Members were asked to report back to the CSF about actions and results 
and feedback will be compiled and shared with ILO in 2011. 
Box 3.3 EU Agency for Fundamental Rights questionnaire  
In 2010, the CSF supported the EU Agency for Fundamental Rights (FRA) with the distribution and follow-up 
of a human rights questionnaire among CSF members. The Agency used the outcomes to prepare a fact 
sheet on a rights-based approach to HIV in the European Union for the 2010 International AIDS Conference. 
This represented a follow-up to the European Parliament Resolution dated 6 July 2010, which called on the 
Commission and the Council to engage the FRA to gather further evidence on the human rights situation of 
people living with HIV/AIDS and other key populations in Europe.  
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Tank. The drug policy position paper21
’In my opinion, the CSF has seized the opportunity to participate in implementing and evaluating the response 
to HIV in the EU and neighbouring countries very well. It is very valuable that there is representation from all 
regions, that CSF representatives speak with one voice and issues discussed are presented at the Think 
Tank’– Think Tank member, Poland. 
 was also disseminated prior to the High Level Meeting on HIV/AIDS in June 
2011 to support national debates on harm reduction policy.  
’The CSF has actively contributed to the meetings of the Think Tank’ – Think Tank member, Netherlands. 
‘The CSF is very useful. It provides European civil society with its own platform and has created a strong 
network of European civil society organisations that goes beyond EU Member States to include Albania, 
Bosnia Herzegovina, Morocco and the Russian Federation. The CSF has also empowered civil society 
organisations to be involved in policy implementation and the meetings allow organisations to hear about new 
ideas and more effective ways of working.’ – European Commission. 
 
3.4 International organisations 
In line with the Communication and Action Plan the Commission engages with international organisations to 
promote HIV/AIDS as a public health and social concern and to keep the issue on the political agenda.  
Policy dialogue takes place through the EU Think Tank and the Civil Society Forum, to which UNAIDS, WHO, 
UNICEF, IOM, UNODC and UNDP are invited. This facilitates debate between EU Member States, neighbouring 
countries, civil society and international agencies. 
The Commission and ECDC have worked closely with UNAIDS to monitor commitments to the 2001 UN General 
Assembly Special Session on HIV/AIDS (UNGASS) Declaration and the Dublin Declaration reporting in 2010.  
The Commission and UNAIDS share strategic information and collaborate on planning and implementing activities. 
Examples include World AIDS Day activities in 2009 and 2010, planning for the 2010 International AIDS 
Conference in Vienna (including joint satellite sessions which focused on access to treatment and key populations), 
and planning for the 2011 European Conference on HIV/AIDS in Tallinn.  
The Commission contributed to the new WHO European Action Plan for HIV/AIDS 2012–2015 and the European 
Health Programme is funding a WHO project to scale up access to harm reduction, treatment and care for injecting 
drug users in the European region. This project covers improved access to and quality of harm reduction, HIV 
treatment, hepatitis C and integrated HIV and TB services, and the promotion of policy development and training. 
 
                                                                    
21 Putting health and human rights first: EU HIV/AIDS Civil Society Forum statement on the future drug policies in the EU and 
beyond, 2011. 
Box 3.5: Evaluation of CSF meetings 
The CSF has evaluated the outcomes of meetings in October 2010 and June 2011.  
Key findings from the October 2010 meeting were: 
• Meeting organisation by the CSF coordination team and networking opportunities were rated 'very 
good' by the majority of the respondents (both 57%).  
• Exchange of information on actions between the meetings was rated 'good' or 'very good' by a large 
majority of respondents (86%).  
• All CSF members share information from the CSF with their colleagues often (32%) or always 
(68%). Many CSF members also share the information with others at the national or regional level 
(often: 52%, always: 33%).  
Key findings from the June 2011 meeting were:  
• Overall the meeting was rated ‘good to very good' by the majority of respondents (90%).  
• Exchange of information on actions between the meetings was rated 'good' or 'very good' by over 
two-thirds of respondents (68%).  
• 95% indicated that the information is useful for their organisation.  
• 62% of CSF members always share the information from the CSF with their colleagues and 32% 
share it often. Many CSF members also share the information with others at the national or regional 
level (often: 27%, always: 45%).  
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There has been a close collaborative working relationship between the Commission and UNODC through support to 
the same projects and to the ‘Drug prevention and information’ programme’.22
The Commission also collaborates with non-UN international organisations. For example, the European Health 
Programme’s SAFE project is working with the International Planned Parenthood Federation on reproductive rights. 
  
3.5 National AIDS Coordinators 
The Commission’s Action Plan proposes regular meetings of national AIDS coordinators to share best practices and 
contribute to policy coherence. The last meeting of national AIDS coordinators took place in Lisbon in October 
2007 and was organised under the auspices of the Portuguese EU Presidency. It may be that no further meetings 
have taken place because other forums, such as the Think Tank, provide sufficient opportunity for dialogue. 
3.6 Northern Dimension Partnership in Public Health and 
Social Well-being 
The Northern Dimension Partnership in Public Health and Social Well-being (NDPHS)23
Reducing the spread of major communicable diseases (including HIV, STI and TB) and preventing non-
communicable diseases is one of the NDPHS’ two priorities. The NDPHS promotes policy dialogue through annual 
partnership conferences, and meetings of the Committee of Senior Representatives (CSR), expert groups and task 
groups. The Commission (Directorate-General for Health and Consumers, Directorate-General for Regional Policy 
and Directorate-General for External Relations) participates in CSR meetings, which are held twice a year, and 
hosted the CSR meeting in October 2011. CSR meetings include updates from the Chair of the NDPHS HIV/AIDS 
and Associated Infections Expert Group. 
 is a partnership involving 
the Commission, 11 countries (Canada, Estonia, Finland, Germany, Iceland, Latvia, Lithuania, Norway, Poland, 
Russian Federation, Sweden), and eight international organisations (Barents Euro-Arctic Council, Baltic Sea States 
Sub-Regional Cooperation, Council of the Baltic Sea States, ILO, IOM, Nordic Council of Ministers, UNAIDS and 
WHO). It aims to promote health and social well-being in Northern Europe by enhancing cooperation, coordination 
and capacity building.  
The HIV/AIDS and Associated Infections Expert Group, which comprises experts from national ministries and 
agencies, NGOs and the research community, focuses on surveillance, policy development and awareness-raising, 
as well as prevention and treatment. Its activities include evaluation of the epidemiological situation and national 
AIDS policies in partner countries, promoting initiatives to prevent HIV and enhancing expert collaboration. The 
Expert Group was actively involved in organising the European AIDS conference ‘HIV in the European Region – 
Unity and Diversity’ in Tallinn in 2011. This included organising sessions on HIV and TB co-infection and on 
regional collaboration, giving presentations and preparing the concluding note. Members of the Expert Group have 
also been actively involved in the EMIS MSM survey (see Box 4.4) and are also involved in implementation of the 
TUBIDU project (see Box 4.3).  
The Expert Group has supported a joint Norwegian-Russian research project on the governance of HIV prevention 
in north-west Russia, to improve prevention strategies, and is collaborating with the Barents HIV/AIDS Programme 
Steering Committee, which implements projects in the Barents Sea Region, covering the Murmansk Region, the 
Archangelsk Region, Karelia and Komi. It has also supported a range of projects to promote improved services in 
the Russian Federation, including provision of low threshold services for people who use drugs in the Leningrad 
Region; collaboration between TB services in the civil and penitentiary systems and AIDS centres to improve 
prevention and management of co-infection in the Murmansk Region, and training for municipal authorities on the 
prevention of drug use and rehabilitation of drug users, also in the Murmansk Region. EU financing has recently 
been secured for a new collaborative project to strengthen HIV and TB prevention and care for people who inject 
drugs in the Kaliningrad Oblast of the Russian Federation (see Box 3.6). The Expert Group is also involved in the H-
CUBE project, which is studying hepatitis B, hepatitis C and HIV in ten countries. A review of best practices in 
integration of social and health care services for people with HIV will commence in 2012 with financing from the 
EU Directorate-General for Regional Policy (DG REGIO). 
  
 
                                                                    
22 Decision 1150/2007/EC of the European Parliament and of the Council of 25 September establishing for the period 2007–
2013 the specific programme 'Drug prevention and information' as part of the General Programme 'Fundamental Rights and 
Justice'. 
23 See www.ndphs.org  
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Box 3.6: Developing services to contain the spread of HIV and TB among people who inject drugs in 
Kaliningrad 
Led by the Kaliningrad NGO YLA, in partnership with Monar Association (Poland), Deutsche AIDS-Hilfe (Germany), 
Ministry of Health of Kaliningrad Oblast, Information Office of the Nordic Council of Ministers in Kaliningrad, 
National AIDS Centre (Poland) and the Centre for Communicable Diseases and AIDS (Lithuania), this project is 
financed by the EU programme ‘Non-state actors and local authorities in development’ for the Baltic Sea Region. 
The objective is to contribute to preventing the spread of HIV and TB in Kaliningrad Oblast. Specifically, the project 
will improve provision of services for drug users by promoting cooperation between government medical and social 
services and NGOs and strengthening the partnership between health officials and NGO activists in Kaliningrad and 
their counterparts from Germany, Poland and Lithuania. The project will develop services to prevent the spread of 
HIV and TB among people who inject drugs, including the establishment of low-threshold service points and the 
improvement of drug treatment. 
3.7 Commission Delegations and Cooperation Agreements 
The Cooperation Council of the European Commission adopted the EU-Ukraine Association Agenda in November 
2009.24
The EU and the Republic of Moldova currently have a Partnership and Cooperation Agreement in place. This 
Agreement is supplemented by the joint EU-Moldova ENP Action Plan.
 This Agenda replaces the Partnership and Cooperation Agreement which had been in place since 1998, and 
the related EU/Ukraine Action Plan. In the public health section of the agenda, the parties agree to cooperate in 
’preventing and controlling communicable diseases, in particular HIV/AIDS, tuberculosis, sexually transmitted 
infections, and hepatitis C and B.’ The agenda also gives Ukraine the ability to participate ’in EU public health 
related networks and working parties, such as the annual network meeting on health information and the 
HIV/AIDS Think Tank.’ In May 2011, the Joint Committee at Senior Official’s Level of the EU-Ukraine Association 
Agenda agreed to a list of the EU-Ukraine Association Agenda priorities for 2011-12. The above-mentioned 
agreement to cooperate on prevention and control of communicable diseases is one of the 90 priorities identified in 
the list. 
25
The EU and the Russian Federation have had a Partnership and Cooperation Agreement in place since 1994. A 
replacement EU-Russia Agreement has been in negotiation since July 2008. At the St. Petersburg summit in May 
2003, the EU and Russia agreed to strengthen their cooperation by creating four ‘common spaces’ within the 
framework of the Partnership and Cooperation Agreement. In the public health section of the 2010 progress report 
EU-Russia Common Economic Space it was reported that ’the Russian Ministry of Health and Social Development 
showed an interest in collaborating on communicable diseases (inter alia pandemic influenza, HIV/AIDS), health 
determinants (alcohol, nutrition, and tobacco), rare diseases and pharmaceuticals.’ 
 The Action Plan makes specific reference 
to Moldova’s ‘participation in dedicated surveillance networks, in particular those collecting data and information on 
HIV/AIDS, sexually transmitted infections, and hepatitis C and B.’ It also refers to the need to ’improve the primary 
health care system and the prevention of diseases, such as the HIV/AIDS epidemic, notably in rural and deprived 
communities and within vulnerable groups.’ The EU and Moldova are in negotiations to replace the existing 
Partnership and Cooperation Agreement with an EU-Moldova Association Agreement. The seventh negotiating 
round for this Agreement took place in July 2011. 
Belarus has no Cooperation Agreement with the EU at present but has participated in Think Tank meetings (see 
below). 
3.8 Meetings and exchange programmes 
Representatives from Belarus, Moldova, the Russian Federation and Ukraine have standing invitations to participate 
in Think Tank meetings. Non-governmental organisations and networks from these countries are invited to 
participate in the Civil Society Forum. As noted above, these meetings facilitate information sharing and exchange 
of experience on the response to HIV. 
3.9 High Level Conference on HIV/AIDS and Human Rights 
This event is planned to take place in the autumn of 2012. 
 
                                                                    
24 See http://www.eeas.europa.eu/ukraine/docs/2010_eu_ukraine_association_agenda_en.pdf 
25 See http://ec.europa.eu/world/enp/pdf/action_plans/moldova_enp_ap_final_en.pdf  
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3.10 Cooperation with the private sector  
The primary mechanism included the Communication on the Commission’s cooperation with the private sector 
centres on the development of new and improved prevention technologies and treatments for HIV and associated 
infections (see Section 4.3 of this report). Much of the research funded through the Research Framework 
Programmes involves close collaboration with the private sector. 
The Commission has also had regular contact and discussions with Gilead Sciences, Inc., the multinational, 
biopharmaceutical company, as well as with EFPIA (European Federation of Pharmaceutical Industries and 
Associations) and FIPRA (Finsbury International Policy & Regulatory Advisers). The focus of this dialogue has 
included topics ranging from the pricing of antiretroviral drugs to HIV testing. 
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4 Effects 
This section focuses on the effects of the various inputs available for implementation of the Communication and 
Action Plan (highlighted by a red box in Figure 4.1). It considers their effects in areas such as political leadership; 
HIV services; treatment and prevention approaches and technologies; surveillance; monitoring and evaluation and 
evidence, scientific advice and dissemination of learning.  
Figure 4.1: Framework for monitoring the HIV Communication and Action Plan: effects of inputs  
 
4.1 Political leadership 
The Communication clearly states that political leadership is an important asset the European Union can provide in 
the fight against HIV/AIDS. The Communication also specifically cites the ongoing problem of HIV-related stigma 
and discrimination in the European Union and neighbouring countries and its impact on the marginalised 
populations who are most vulnerable and most affected by the epidemic. Most importantly, it recognises the need 
for political leadership to ensure that the health and rights of these populations are promoted. 
Political leadership has the ability to shape the HIV response in a number of different ways and settings. This 
includes the impact of actions taken by EU Presidencies – although no respondents identified a specific effect from 
an EU Presidency, despite the fact that the Spanish Presidency included a major focus on HIV. It also includes the 
outcomes of action taken by the Think Tank and the Civil Society Forum and the results of activities funded by the 
European Health Programme.  
Respondents’ views on the effects of the Think Tank on political leadership were varied. A number of countries 
expressed positive views. For example, the response from the Moldova representative suggested that Think Tank 
action has contributed to HIV being a top public health priority in the country and a permanent topic on the 
political agenda. The Bulgarian response also suggested that the actions of the Think Tank have kept HIV on the 
political agenda, while the Slovak Republic indicated that these actions had helped to ‘improve’ political leadership 
in the country. Ukraine felt the actions had helped the country to develop a sustainable state response to HIV, 
including legislative changes and decision-making based on European initiatives and evidence based practices. 
However, two countries suggested that there had been little impact at national level.  
Members of the Civil Society Forum were also asked about the effects of the Think Tank’s actions on political 
leadership. Although only one civil society representative answered this question, the response was positive: 
‘We believe that the continued participation of the Portuguese national AIDS coordinator in the Think Tank 
meetings has contributed to increased political leadership and better national HIV policy development, 
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actively involving civil society and influenced by the best practices from around Europe, as well as by the EC 
Communication and Action Plan’ – CSF member, Portugal. 
Similarly, there were diverse views about the effects of action taken by the Civil Society Forum on political 
leadership, with some respondents suggesting that it has helped to keep HIV on the political agenda in Europe, 
whereas others suggested that there had been no effects. The CSF representative from Ukraine noted that an 
advocacy campaign launched as the result of its participation in the CSF was so successful that the Ukrainian 
President had requested 100% state funding for the programme in 2011 and 2012. The representative from 
Austria reported that documents published by the European Commission or the CSF helped to secure further 
commitment from the various stakeholders and provide guidelines and a useful basis for future work. 
According to the Commission’s Executive Agency for Health and Consumers (EAHC), financial support from the 
European Health Programme to four conferences resulted in stronger leadership on HIV (see Box 4.1). 
Box 4.1: Support for conferences strengthens leadership 
 
• The International Harm Reduction Association (IHRA)’s 21st International Conference in 2010 provided an 
opportunity to raise awareness, exchange knowledge, improve advocacy, and increase support and capacity 
for harm reduction in Europe. 
• The XVIII International AIDS Conference in 2010 received targeted support – from EAHC via UNAIDS – to 
strengthen community action and mobilisation through civil society participation in the conference; operate the 
Global Village organisation; provide scholarships for participants from Eastern European Union countries and 
provide much-needed translation and interpretation to broaden the reach of the conference. In addition, four 
satellite sessions were held to improve knowledge sharing and coordination as part of the European response 
to HIV.  
• The European AIDS Conference 2011 HIV in Europe – Unity and Diversity held in Tallinn, Estonia represented 
an opportunity for capacity-building to enable public health experts to lead the response. The conference had 
a special focus on vulnerable groups and health systems, particularly in the Baltic region and ENP countries, 
where HIV is having the most serious impact. 
• The Future of European Prevention among MSM (FEMP 2011). This regional conference was an opportunity to 
focus discussion and action planning on a population that is central to the HIV response in Europe. 
In the Communication, the Commission expressly highlights support for monitoring the implementation of 
international commitments at country and European level, and for international organisations such as UNAIDS in 
their work to mobilise political leadership in Eastern Europe. According to UNAIDS, its engagement with the 
Commission has had two major effects linked to political leadership. Firstly, it has helped maintain the visibility of 
HIV as an issue in Europe. Secondly, it has kept HIV on the political agenda. More specifically, UNAIDS cites a 
diverse range of effects from its engagement with the Commission including:  
• The participation of senior political leaders in the XVIII International AIDS Conference 
• EU statements on World AIDS Days in 2009 and 2010 
• Government support and participation in the regional HIV in Europe conference 
• Inter-agency collaboration on the monitoring of the Dublin Declaration. 
UNAIDS also identified a series of challenges related to political leadership, including fully mobilising political 
leadership in neighbouring countries, particularly for harm reduction programmes in the Russian Federation, and 
the limited participation of European leaders in the High Level Meeting on AIDS in June 2011. 
‘…in the absence of leadership there is a strong risk for a rebound of the epidemic in Europe, as indicated by 
increasing new infections among men who have sex with men, and a continuous growth in the number of 
people requiring lifelong sustained treatment, which in some Member States represents a substantive part of 
the health budget.’ – UNAIDS. 
4.2 HIV services 
This section explores the extent to which the Communication and Action Plan has had positive effects on the 
provision of key services, such as harm reduction programmes, HIV testing and counselling, antiretroviral therapy 
and services for co-infections such as TB and hepatitis. It focuses on services in the most-affected Member States, 
neighbourhood countries and the Russian Federation. It also focuses on services in particular settings (e.g. prisons) 
and for key populations, including men who have sex with men, people who inject drugs, migrants and sex 
workers. 
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Support for key services 
The Communication is very clear about the need for harm reduction programmes as part of an effective response 
to HIV. The Global Fund to Fight AIDS, Tuberculosis and Malaria has been very active in financing harm reduction 
programmes in Eastern Europe and Central Asia. As a major contributor to the Global Fund, the European 
Commission has made significant efforts to increase the availability of harm reduction services for people who 
inject drugs in the region (see Box 4.2). However, there are major concerns about the extent to which countries 
can sustain these services once Global Fund support ends. For example, there have been reports of an increase in 
new HIV infections among drug users in Romania in 2011.  
 
HIV testing and counselling services have been supported in a number of ways. For example, the Think Tank 
representative from Slovakia commented that the involvement of an NGO, Odysseus, in the Civil Society Forum had 
benefitted their HIV testing and counselling services for people at risk of HIV infection. The European Health 
Programme has been supporting a project (HIV-COBATEST) focused on community-based HIV testing practices in 
Europe. This project seeks to promote early HIV diagnosis in Europe by improving the implementation, monitoring 
and evaluation of community-based counselling and testing practices. Elements of the project include collecting 
data in many countries on the implementation of community-based HIV testing programmes. It will also explore 
the likely effect of new rapid, saliva-based HIV tests on community-based HIV testing. 
In 2010, ECDC produced guidelines on HIV testing bringing together evidence of the individual and public health 
effects of HIV testing. Through its contribution to the Global Fund, the Commission has supported the provision of 
HIV testing to a large number of people (see Box 4.2).26
Concern has been raised about the relatively low level of 
 
antiretroviral
It is therefore encouraging that the Commission has been able to make a significant contribution to scaling up 
antiretroviral therapy in Eastern Europe through its contribution to the Global Fund (see Box 4.2). Nevertheless, 
there are still serious concerns about the extent to which some countries will be able to sustain antiretroviral 
therapy when Global Fund support comes to an end.  
 coverage in Eastern Europe. For example, in 
their report, UNAIDS commented that in 2009 only 19% of people in acute need had access to antiretroviral 
treatment in Eastern Europe. This places the region alongside North Africa as one of those with the lowest 
coverage globally, with only half of the coverage found in sub-Saharan Africa (37.4%) despite having much larger 
numbers of people in need. 
ECDC has also been implementing a project to explore new ways in which treatment is being used. This project is 
reviewing published scientific literature in order to inform prevention decision-making in the region.  
Meanwhile, the European Health Programme has been supporting a number of projects tackling co-infections, such 
as TB and hepatitis (see Box 4.3). 
  
 
                                                                    
26 A very large proportion of those tested are in the Russian Federation. This number includes testing among key populations and 
the general population, whereas in other countries testing among key populations is reported separately from testing of the 
general population. Where countries report numbers tested among key populations separately, these numbers have been used. 
Box 4.2: European Commission pro rata contribution to results achieved through Global Fund 
financing 
Since the formation of the Global Fund, the European Commission has provided more than USD 1.2 billion 
in financing, accounting for 6.2% of the Fund’s total resources. Based on a review of results in Grant 
Performance Reports from 18 countries within the region and allocating these results to Commission funds 
on a pro rata basis, it is estimated that the Commission has supported provision of:  
• Harm reduction services for over 35 000 people who inject drugs 
• Opioid substitution therapy for almost 800 people who inject drugs 
• HIV prevention programmes for over 10 000 sex workers and their clients 
• HIV prevention programmes for over 15 000 men who have sex with men 
• HIV prevention programmes for over 25 000 prisoners 
• Almost five million condoms 
• HIV testing and counselling for almost two million people 
• Antiretroviral therapy for over 6 000 people. 
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Expansion of services in most-affected regions 
Support for the Communication and Action Plan has had a strong focus on the expansion of services in regions and 
countries most-affected by HIV, such as Ukraine and Russia. Much of the support from the Global Fund in the 
region is focused on these two countries and this is seen in the results achieved (see Box 4.2). This is also 
reflected in the strategy and actions of other international organisations working with the Commission. For 
example, UNAIDS reports that its priorities and actions are focused on those regions identified as priority regions in 
the Communication and Action Plan. The UNAIDS Regional Support Team is based in Moscow and provides support 
to many countries in the region. The new WHO Europe strategy also has similar regional priorities. The agenda of 
the Civil Society Forum is also based on priorities within the Communication and Action Plan and therefore has 
placed specific emphasis on Eastern Europe, (Ukraine and Russia in particular). The European Health Programme 
also supports projects focused on those EU Member States most affected by HIV, such as the Baltic countries. For 
example, TUBIDU (see Box 4.3) addresses the TB epidemic among vulnerable groups in the Baltic and the 
European Union countries in the east of Europe. 
Expansion of services for key populations 
Support for the Communication and Action Plan has had a strong focus on expanding services for those 
populations most-affected by HIV. 
Through the Global Fund, the Commission has financed the expansion of services for men who have sex with 
men (MSM) (see Box 4.2). In addition, the European Health Programme has supported a number of projects with 
particular emphasis on MSM. These include important international conferences (e.g. FEMP27), major surveys (e.g. 
EMIS28) and initiatives which aim to link surveillance and targeted prevention (e.g. SIALON II29
ECDC has also focused on action to improve prevention of HIV and STI among MSM. These include a 2009 study 
on the effectiveness of behavioural and psychosocial HIV/STI prevention activities for MSM in Europe
) (see Box 4.4).  
30 and a 
special issue of Eurosurveillance devoted to the issue of HIV and STI among MSM.31
Other activities supported by ECDC include: 
 
• A seminar in the European Parliament to raise awareness about the high rates of HIV and STI among MSM 
in Europe. 
• An ongoing project to assess the effectiveness of prevention interventions targeting MSM. 
• Work to formulate a strategy for promoting sexual health in the context of disease prevention among MSM 
in Europe. 
• Partnership with EMIS (see Box 4.4) to conduct regional analysis of the data collected. 
• Contributing to scientific presentations at the FEMP Conference in November 2011 (see Box 4.4) 
 
                                                                    
27 See www.femp2011.eu  
28 See www.emis-project.eu  
29 See www.sialon.eu  
30 Effectiveness of behavioural and psychosocial HIV/STI prevention interventions for MSM in Europe. Technical report. Revised 
edition, December 2009. ECDC, Stockholm.  
31 HIV/AIDS and other STI in men who have sex with men – A continuous challenge for public health. Eurosurveillance Special 
Edition, Volume 14, Issue 47, December 2009. ECDC, Stockholm.  
Box 4.3: Examples of projects within the European Health Programme focused on co-
infections 
TUBIDU is a project to empower civil society and the public health system to fight the TB epidemic 
among vulnerable groups, including people who inject drugs. This involves efforts to engage harm 
reduction service providers and community-based organisations in responding to TB. 
The Imp.Ac.T project seeks to improve access to HIV/TB testing for marginalised groups, such as 
problematic drug users, people who inject drugs and migrant drug users. Approaches include adopting 
innovative testing strategies, such as HIV and TB rapid testing in low threshold centres. 
The European Health Programme is also establishing EU-HEP-SCREEN which will offer hepatitis B and 
C screening for migrants in the European Union. 
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The Civil Society Forum was reported to have been influential in strengthening the European MSM network, which 
in turn was considered to have made an impact on addressing the prevention needs of MSM communities across 
Europe. In addition, the CSF’s agenda is based on the Communication and Action Plan and has therefore had a 
strong focus on most-affected populations, including MSM. Box 4.5 provides an example of the development of 
new NGO services in Portugal based on priorities expressed in the Communication. 
Through the Global Fund, the Commission has financed the expansion of services for people who inject drugs (see 
Box 4.2). In addition, the European Health Programme has supported a number of projects focused on people 
who inject drugs, including TUBIDU and Imp.Ac.T (see Box 4.3). The Commission’s Directorate General for 
Justice is also funding a number of projects through the European Health Programme and EAHC related to drugs 
and HIV. These include support for a project entitled ‘Connections’ launched in 2007 and coordinated by the 
European Institute of Social Services (EISS) of the University of Kent. The project aims to integrate responses to 
drugs and infections across the European criminal justice systems. It focuses on the potential for partnerships 
within the criminal justice systems of the EU Member States to develop responses to drugs and related-infections, 
particularly HIV/AIDS and hepatitis. The project will facilitate the introduction and promotion of more effective, 
comprehensive, evidence-based policies and services at national and European level to respond to drugs and 
infections in prisons and within the wider context of the criminal justice system.  
 
Through the Global Fund, the Commission has financed the expansion of HIV-related services in prisons (see Box 
4.2). In addition, the European Health Programme is supporting a project (HPYP) to promote the health of young 
prisoners by sharing a health promotion toolkit across EU Member States. The toolkit covers issues relating to 
infectious diseases, sexual health, drug use and mental health. The Think Tank has had discussions related to HIV 
testing policy in prisons. The CSF’s agenda has also had a strong focus on prisoners. 
The European Health Programme is supporting a number of projects focused on the health of migrants and 
ethnic minorities. These include EU-HEP-SCREEN, coordinated by the Erasmus University Medical Center in 
Rotterdam, which aims to assess, describe and communicate to public health professionals the tools and conditions 
necessary to implementing successful and cost effective screening programmes for hepatitis B and C among 
migrants in the European Union. Another project, SRAP, focuses on preventing addiction among Roma and Sinti 
communities. The Think Tank has also had discussions relating to the health of migrants in Europe.  
ECDC has also done significant work in the area of migrant health including the production of a series of five 
reports covering the epidemiology of HIV and AIDS;32, access to HIV prevention, treatment and care33
 
                                                                    
32 Migrant health: Epidemiology of HIV and AIDS in migrant communities and ethnic minorities in EU/EEA countries. Technical 
report. March 2010. ECDC, Stockholm. 
 and HIV 
33 Migrant health: Access to HIV prevention, treatment and care for migrant populations in EU/EEA countries. Technical report. 
July 2009. ECDC, Stockholm. 
Box 4.5: New and innovative services developed in Portugal reflecting the Communication’s 
emphasis on key vulnerable populations, including MSM 
‘In light of the Communication’s emphasis on key vulnerable populations and following similar initiatives in 
various European countries in 2010, GAT opened the first peer-to-peer VCT centre in Portugal (CheckpointLX), 
specifically targeting the MSM population in Lisbon. To implement this innovative approach in Portugal, 
advocacy was necessary to adopt changes to national law in order to allow for community-based HIV testing. 
Due to the success of the MSM initiative, similar VCT centres are now being programmed, directed specifically at 
IDUs, CSWs and migrants, according to the latest testing guidelines from ECDC, WHO Europe and EMCDDA.’ 
Box 4.4: Examples of projects within the European Health Programme focused on MSM 
‘The Future of European Prevention among MSM’ (FEMP) conference in Stockholm in November 2011. 
The European MSM Internet Survey (EMIS) was conducted among MSM across Europe and attracted 
over 180 000 respondents from 38 countries. 
SIALON II focuses on building the capacity of NGOs and public health institutions to conduct local 
surveillance activities among MSM and to use the data gathered to develop appropriate HIV prevention 
activities for MSM. 
 
 
 
 
SPECIAL REPORT Monitoring implementation of the Commission Communication and Action Plan on HIV/AIDS 
 
 
 
31 
 
 
 
testing and counselling34 in migrants; issues relating to infectious diseases, including HIV and migrants;35 and 
improving data comparability and definitions of migration used within the EU/EEA/EFTA.36
Through the Global Fund, the Commission has financed the expansion of services for sex workers (see Box 4.2). 
In addition, the European Health Programme has supported a number of projects for sex workers, including 
Bordernet
 
37
4.3 New treatment and prevention technologies 
 which seeks to scale up HIV and STI prevention, diagnosis and treatment across sectors and borders 
in Central, Eastern and South-Eastern Europe. The project focuses on a number of key populations affected by HIV, 
including sex workers. 
The Communication states that the Commission encourages long-term public and private investment into research 
for the development of new and improved prevention technologies and treatments for HIV and associated 
infections. As discussed in Section 2, the Commission has provided funding for research on HIV and associated 
infections through its research framework and health programmes. Key findings concerning the effects of 
Commission-supported actions are summarised below.  
Progress in developing new prevention technologies  
Commission funding has supported innovative research on HIV prevention (see Box 4.6). 
Box 4.6: HIV prevention research 
EUROPRISE38
Progress in developing new treatments 
 promotes integrated research on HIV vaccines and microbicides and is exploring whether combined 
use of these two technologies can lead to more effective prevention. EUROPRISE partners have been involved in 
31 clinical trials and have produced more than 200 peer-reviewed publications. The network has also played an 
important role in promoting a harmonised experimental approach and use of standardised reagents.  
Commission funding through the Sixth and Seventh Framework Programmes has also supported important 
research to develop novel HIV drugs and clinical trials of new treatment combinations (see Box 4.7). 
Box 4.7: HIV treatment research 
The THINC project has taken forward the development of a new class of anti-HIV drug, building on research 
conducted by the TRIhO project under the Sixth Framework Programme. The consortium has worked in 
partnership with the pharmaceutical company Tibotec and has successfully negotiated with Pfizer in the UK for 
further development studies and clinical trials after project funding ends.  
The NEAT network of excellence is implementing clinical trials for new treatment combinations. NEAT has recently 
commenced a randomised clinical trial that will enrol more than 800 patients in 15 European countries, a clinical 
trial of this magnitude is unprecedented in Europe. 
Increased research capacity 
Commission support has strengthened research capacity both in Europe and in developing countries affected by 
the HIV epidemic (see Box 4.8).  
  
 
                                                                    
34 Migrant health: HIV testing and counselling in migrant populations and ethnic minorities in EU/EEA/EFTA Member States. 
Technical report. August 2011. ECDC, Stockholm. 
35 Migrant health: Background note to the ‘ECDC report on migration and infectious diseases in the EU’. Technical report. July 
2009. ECDC, Stockholm. 
36 Improving HIV data comparability in migrant populations and ethnic minorities in EU/EEA/EFTA countries: findings from a 
literature review and expert panel. Technical report. August 2011. ECDC, Stockholm. 
37 See www.bordernet.eu  
38 For more information about this and other research projects referred to in this section see www.ec.europa.eu/research/health  
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Box 4.8: Building capacity for research 
 
Under the Sixth Framework Programme additional funds have been committed to the European and Developing 
Countries Clinical Trials Partnership (EDCTP) to support coordination, capacity building and advanced clinical trials. 
Since 2003, the EDCTP has provided EUR 102 million to fund 24 clinical trials on HIV and AIDS. 
 
The NEAT network (see Box 10) is also building capacity in order to conduct pan-European clinical trials. 
 
The EUROPRISE network has established a pan-European PhD training programme with over 44 PhD students. 
Improved coordination and collaboration 
Commission support to a range of initiatives (see Box 4.9) has improved coordination of research in Europe and 
promoted increased collaboration between European and international researchers and between researchers and 
industry. 
Box 4.9 Research coordination and collaboration 
 
Under the Seventh Framework Programme, the ERA-NET HIVERA project is being funded to improve coordination 
and integration of national HIV research programmes and activities.  
 
The NEAT network of excellence aims to promote European collaboration in HIV and AIDS clinical research. The 
network, coordinated by the Istituto Superiore di Sanita in Italy, involves 41 partners and has resulted in 
collaboration between European researchers on more than 21 clinical trials. 
 
Other examples of research collaboration, described in more detail elsewhere in this report, include EuroSIDA, 
Eurocoord, the EUROPRISE network, which has established collaboration between European and US researchers 
and with industry partners such as Novartis and GSK, and the THINC project, which is being implemented by a 
consortium of 10 European partners and coordinated by Leuven University in Belgium.  
4.4 Surveillance 
The Commission has asked ECDC to provide data for a more accurate understanding of the HIV epidemic in Europe, 
including HIV incidence and prevalence, behavioural data, and undiagnosed HIV infections. This highlights the 
need for second generation and behavioural surveillance and social science research to be intensified to better 
understand the dynamics of the epidemic in Europe, in order to inform policy and programming. Key findings 
concerning the effects of Commission-supported action are summarised below. 
Significant improvements in HIV-related epidemiological surveillance 
in Europe 
ECDC has contributed to important progress in biological surveillance of the epidemic in Europe. Surveillance data 
on HIV and AIDS cases is collected annually and submitted by national HIV/AIDS surveillance contact points in the 
Member States to The European Surveillance system (TESSy). ECDC has helped to ensure that a harmonised 
surveillance system is in place across Europe and that almost all EU Member States, as well as several 
neighbouring countries, report epidemiological data. Responses indicate that the work of ECDC, in cooperation with 
Member States, has contributed to strengthening epidemiological surveillance and surveillance reporting. 
ECDC has focused its efforts on supporting countries to improve surveillance systems through country visits, 
surveillance network meetings and support during surveillance uploading and reporting. This has improved the 
comprehensiveness and quality of surveillance. ECDC also coordinates the HIV/AIDS expert network. Annual 
meetings of national contact points from EU and EEA countries have promoted the sharing of experience and 
information as well as providing an opportunity to update experts on new developments in surveillance and 
monitoring and evaluation.  
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Box 4.10: Towards a more accurate picture of HIV prevalence and incidence in Europe 
 
An ECDC project will offer a more accurate picture of HIV prevalence in Europe by providing a better estimate of 
the proportion of people living with HIV who are undiagnosed. The project has reviewed models used to estimate 
HIV prevalence in low-level epidemics and an adapted model is currently being piloted in four EU countries. A 
database for HIV prevalence studies is being developed for use by experts and researchers in Member States.  
Another ECDC project will provide a more accurate picture of HIV incidence in Europe by developing a model to 
monitor recently acquired infections. The project will improve understanding of recent transmission through better 
estimation of the proportion of recently infected individuals among all new HIV diagnoses. 
Collaboration between ECDC and WHO’s Regional Office for Europe since January 2008 has resulted in effective 
coordination of HIV and AIDS surveillance in Europe. Coordination has also been strengthened through the 
HIV/AIDS expert network. ECDC has improved the dissemination of surveillance data, publishing the annual joint 
HIV and AIDS surveillance report and scientific articles presenting surveillance data in Eurosurveillance.  
Initial improvements in behavioural surveillance 
ECDC is supporting a major project to enhance behavioural surveillance in Europe. The project has published a 
report analysing HIV and STI-related behavioural surveillance programmes in European countries39 and prepared a 
plan for implementing behavioural surveillance including a set of key indicators. Technical guidance and a toolkit40
Steps taken to improve HIV-TB co-infection surveillance 
 
have been developed to support Member States in implementing behavioural surveillance and the approach is 
being piloted in two EU countries. While respondents welcome these developments, some suggested that there is 
still scope to strengthen second generation surveillance.  
Projects supported by ECDC and EAHC are contributing to better surveillance of HIV-TB co-infection, particularly 
among the most vulnerable population groups (see Box 4.11).  
Box 4.11: Developing better surveillance systems to monitor HIV and TB infection 
ECDC is supporting a project which aims to improve HIV-TB surveillance by mapping co-infection and related 
surveillance systems and practices in Europe. The project has conducted a systematic review to determine the 
burden of co-infection in EU and EEA countries and an online survey of national TB surveillance contact points to 
assess the burden of co-infection, clinical management of co-infection and current approaches to monitoring HIV 
co-infection in TB surveillance systems. 
A project to improve access to HIV/TB testing for marginalised groups (IMPACT), which commenced in September 
2010 with funding from the European Health Programme, will contribute to developing a new accurate, timely and 
comparable surveillance system for monitoring trends in HIV and TB infection among people who inject drugs, 
including migrant drug users. The project is expected to result in standardised reporting, thereby providing a more 
reliable picture of the HIV and TB epidemics among these vulnerable groups at country and European level. 
Significant progress in European surveillance among key populations 
European agencies, such as EMCDDA, and projects funded by the Commission, including through the European 
Health Programme, have contributed to improved understanding of the impact of the HIV epidemic among the 
population groups most affected in Europe, in particular people who inject drugs and men who have sex with men. 
EMCDDA reports that it provides the EU and its Member States with objective, accurate, comparable information 
on drugs and drug addiction, including HIV-related information on injecting risk behaviour, HIV incidence and 
prevalence among people who inject drugs and responses to drug use, which include harm reduction, treatment 
and HIV prevention measures. Data is published in the annual Statistical Bulletin and the EMCDDA Annual Report 
on the state of the drugs problem in Europe.41
 
                                                                    
39 Mapping of HIV/STI behavioural surveillance in Europe. Technical report. September 2009. ECDC, Stockholm.  
  
40 See www.ecdc.europa.eu  
41 See www.emcdda.europa.eu  
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EMCDDA collects data in collaboration with EU Member States, through an EMCDDA focal point in each country and 
Drug-Related Infectious Diseases (DRID) experts, ECDC and the WHO Regional Office for Europe. Comprehensive 
data is collected on the availability, provision and coverage of interventions to prevent infections among drug users 
including, for example, on needle and syringe programmes and the proportion of prisoners receiving opioid 
substitution therapy. The DRID project has enhanced networking and exchange of information between European 
experts, provided technical assistance to strengthen data collection capacity and produced revised guidance and a 
tool kit for DRID data collection. 
Specific support has also contributed to enhanced surveillance among MSM. UNAIDS, for example, highlighted the 
significant progress that has been made in this area as a result of innovative activities supported by the 
Commission. One example is the European MSM Internet Survey (EMIS) project, which has generated valuable 
behavioural data related to MSM. Another is the SIALON II project (see Box 4.12). 
Box 4.12: Innovative approaches to surveillance among MSM 
The SIALON II project, funded through the European Health Programme and implemented in cooperation with 
WHO and UNAIDS, focuses on the use of innovative surveillance methods among MSM as well as assessment of 
HIV prevention needs and interventions. The project will develop approaches to epidemiological surveillance that 
are appropriate to the local context and improve the capacity of public health institutions and MSM NGOs to use 
innovative methods to collect serological and behavioural data among hard-to-reach MSM.  
This is expected to improve issues such as the estimation of HIV and STI incidence, prevalence and undiagnosed 
infections in the MSM population. The project is also expected to contribute to greater harmonisation of 
surveillance methodologies, generate comparable data on epidemiological and behavioural indicators for MSM 
communities, identify unmet prevention needs and strengthen networking between organisations working on MSM. 
4.5 Monitoring and evaluation 
The Communication highlights the need for national surveillance systems to be fully compatible with international 
requirements and for all countries to report regularly on their HIV/AIDS epidemics. Key findings concerning the 
effects of Commission-supported actions are summarised below.  
Monitoring has improved significantly 
Country responses suggest that Commission-supported activities, in particular the work of ECDC, have contributed 
to significant progress in strengthening monitoring. Specifically, ECDC efforts have resulted in a considerably 
improved reporting on the implementation of the Dublin Declaration as well as increased UNGASS reporting.  
ECDC has worked closely with UNAIDS and WHO on this and has coordinated a country-led approach through an 
advisory group that includes representatives from EU Member States and other countries and from the EU Civil 
Society Forum. In 2009, ECDC hosted a monitoring and evaluation workshop to support countries in their reporting 
for the Dublin Declaration and UNGASS. This resulted in very high regional response rates both for Dublin and 
UNGASS reporting. For Dublin reporting, responses were received from 49 countries. This included responses from 
12 countries42 that did not submit returns to UNGASS in 2008. In September 2010, ECDC published an indicator-
based progress report43 on implementing the Dublin Declaration which describes how countries in the region are 
responding to the HIV epidemic and identifies clear recommendations for improving and monitoring the response.44
  
  
 
                                                                    
42 Andorra, Czech Republic, Denmark, Iceland, Italy, Luxembourg, Malta, Norway, Portugal, San Marino, Slovakia and 
Turkmenistan. 
43 Implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2010 progress report. 
Special report. September 2010. ECDC, Stockholm.  
44 The Vilnius and Bremen Declarations are not actively monitored as the Dublin Declaration encapsulates key commitments. 
Follow up to Bremen is through the ‘Bremen process’, which focuses on ensuring fair and affordable prices for antiretroviral drugs. 
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Good progress in developing regionally-relevant indicators and 
improving monitoring tools 
ECDC work is now focusing on improving the usefulness of indicators for regional monitoring and further 
harmonising indicators with Global AIDS Response Progress Reporting in preparation for an additional round of 
data collection on Dublin indicators in 2012.  
ECDC has successfully consulted with EU Member States to reach consensus on a set of regionally specific and 
harmonised indicators to monitor the HIV response in Europe, including indicators related to migrants, prisoners, 
ART and late diagnosis, as well as a streamlined approach to reporting to ECDC, UNAIDS and WHO. This is 
expected to reduce the reporting burden on countries. ECDC also supported the Commission in hosting a side 
event on the regionalisation of monitoring the response to HIV at the United Nations High Level Meeting on AIDS 
in New York in 2011.  
EMCDDA has developed a comprehensive set of key indicators and core datasets in cooperation with national focal 
points and external technical experts. The key indicators, which include monitoring the extent of infectious 
diseases — primarily HIV, hepatitis C and hepatitis B infection — among people who inject drugs, have become the 
accepted European standard for drug monitoring and have also been influential internationally. EMCDDA has also 
taken steps to improve the quality of monitoring tools, for example, organising expert meetings to refine and 
standardise data collection tools and providing technical input to the review of UNODC data collection tools. 
EMCDDA is also collaborating with ECDC to share data for the purposes of monitoring the Dublin Declaration. 
4.6 Evidence, scientific advice and dissemination of good 
practice 
The Communication emphasises the importance of evidence-based policy and programming, which is supported by 
accurate data on factors driving the epidemic in Europe and sound research on issues such as clinical management. 
It also emphasises the importance of scientific advice and the dissemination of learning. Key findings concerning 
the effects of Commission-supported actions are summarised below. 
Operational research, surveys and scientific research have 
strengthened the evidence base 
Commission-supported activities are strengthening the evidence base. For example, operational research (see Box 
4.13) will generate evidence to improve the approach to and the cost-effectiveness of HIV testing and screening 
for HIV, STI, and hepatitis B and C, with particular reference to those population groups most at risk in the 
European region. Operational research will also help improve the monitoring and management of drug resistance 
in the region. 
EU-funded research is also generating important evidence which will improve the clinical management of HIV and 
the control of HIV drug resistance. The research is exploring a range of issues including ways to improve clinical 
management and quality of life for adults and children with HIV and for patients with HIV and other infections such 
as TB. Research will also focus on improving knowledge of resistance to existing drugs and the prevention and 
management of drug resistance (see Box 4.14. 
  
 
 
 
 
Monitoring implementation of the Commission Communication and Action Plan on HIV/AIDS SPECIAL REPORT 
 
 
 
36 
 
 
 
Box 4.13: Examples of operational research  
Through the European Health Programme, the HIV COBATEST project, which started in 2010, aims to improve community-
based HIV counselling and testing in Europe, in order to promote early HIV diagnosis. The project will review community-
based counselling and testing programmes in order to identify good practices and develop a set of core indicators for related 
monitoring and evaluation. It will also assess the acceptability, feasibility and impact of introducing rapid oral tests in 
community-based counselling and testing programmes.  
The improving access to HIV/TB testing for marginalised groups (IMPACT) project aims to broaden access to HIV and TB 
testing, prevention, treatment and care for vulnerable groups including drug users and migrant drug users. The project will 
raise awareness among health providers of the importance of testing uptake and identify and promote innovative testing 
strategies for vulnerable groups. To date, the project has developed a protocol for implementing HIV and TB rapid tests in 
low-threshold facilities, produced a training manual and conducted capacity-building workshops, in particular for the 
providers of outreach services.  
An ECDC project is assessing the relevance of novel approaches to testing for HIV, STI and hepatitis B and C in Europe. 
Based on a review of the literature and of testing technologies used within and outside of healthcare settings, the project 
will produce a report setting out key findings and implications for public health.  
ECDC is also investigating the cost-effectiveness of screening strategies for HIV, hepatitis B and hepatitis C, based on a 
review of available models and cost-effectiveness estimates. The project will identify the most appropriate models to assess 
the impact of screening in the European context and develop and test a tool kit for estimating cost-effectiveness.  
A project to assess the value to public health of HIV drug resistance monitoring is also being supported by ECDC. To date, 
the project has assessed the added value of systematically monitoring antiretroviral drug resistance among newly-diagnosed 
individuals with HIV in EU and EEA countries, and of using the genetic sequence data collected as part of antiretroviral drug 
resistance monitoring at EU level. 
The TUBIDU project, which started in 2010 and is being organised through the European Health Programme, is promoting 
cooperation between harm reduction service providers and community organisations. It is expected to reduce the burden of 
TB among people living with HIV and people who inject drugs by improving planning, targeting responses, developing 
guidelines for service delivery and addressing barriers to accessing services.  
 
Box 4.14: Examples of clinical research 
EuroSIDA is an observational study following up more than 16 000 people with HIV infection in 32 countries, including all EU 
Member States. The study has generated valuable data on the impact of antiretroviral drugs on patient outcomes. EuroSIDA 
has published 130 peer-reviewed publications and influenced patient treatment and related guidelines, as well as providing 
the basis for further cohort collaboration.  
The CASCADE study is following up patients for whom the date of HIV infection can be reasonably well estimated. The 
study, which has access to data from 20 000 HIV-infected individuals from 26 cohorts in 15 European countries, Australia, 
Canada and Sub-Saharan African countries, has provided important insight into the course of HIV infection, thereby 
improving treatment strategies. CASCADE has produced 50 joint, peer-reviewed publications and presentations at 
international conferences.  
The PENTA/ECS study, which follows up on pregnant women and children with HIV, is improving the clinical management 
and treatment of HIV-infected pregnant women and paediatric infection. Implemented by nine partners, it conducts 
epidemiological studies of mother-to-child transmission, clinical trials and training, and has published 41 papers in peer-
reviewed journals. PENTA guidelines on use of antiretroviral therapy in paediatric infection are widely used and have 
influenced WHO guidance. The training programme for health workers caring for HIV-infected children has been 
incorporated into curricula (e.g. Oxford University’s Postgraduate Diploma in Paediatric Infectious Disease). 
EuroSIDA, CASCADE and PENTA are also involved in EuroCoord, a network of 23 partners established in January 2011. 
Eurocoord aims to improve the clinical management and quality of life of people with HIV, as well as to explore differences 
within sub-groups. It has access to data from over 250 000 HIV patients, one of the largest cohorts in the world, and will 
provide valuable information on issues such as patient response to therapy, implications of long-term infection and long-
term treatment, impact of TB co-infection and management of hepatitis co-infection. 
CHAIN, a substantial epidemiological and research project with a particular focus on Eastern Europe, aims to improve 
current knowledge on resistance to existing drugs and the prevention and management of drug resistance. The project will 
develop new laboratory tools to measure drug resistance, improve understanding of the clinical implications of drug 
resistance, develop strategies for the management of individuals with drug-resistant infection, build scientific and clinical 
expertise and provide evidence-based recommendations for limiting the emergence and transmission of drug resistant HIV. 
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Valuable evidence is also being generated through surveys. As noted earlier in this report, ECDC is a partner in the 
Commission-funded European MSM Internet Survey (EMIS), conducting regional analysis of data collected with a 
view to publishing the survey report in 2012 in collaboration with the EMIS consortium. 
Evidence is informing policy and programming 
Evidence generated is being put into practice, informing policy and programming. For example, ECDC published 
updated guidance on HIV testing in 2010, based on a systematic review of the evidence on the individual and 
public health effects of HIV testing and consultation with Member States, civil society and disease experts. The 
guidance was launched on World AIDS Day at an event in the European Parliament.  
EMCDDA and ECDC have developed guidance on the prevention of HIV and other infections among people who 
inject drugs. The guidance reflects the evidence collected by a desk review and a systematic review of the 
evidence on prevention interventions in this population as well as feedback from a technical consultation. The 
evidence papers and the guidance were published in 2011. Efforts to generate better evidence on drug use and 
HIV and effective interventions appear to have contributed to the adoption of evidence-based approaches to HIV 
prevention and harm reduction in countries across the region.  
ECDC work to strengthen the evidence base on HIV and STI prevention among MSM has contributed to 
coordinated EU action. ECDC has also done significant work in the area of migrants and HIV in the EU and on 
treatment as prevention, in order to inform the development of policy and programming. 
‘Especially in relation to HIV testing, HIV prevention for MSM and HIV prevention among IDU, the knowledge 
basis established [through activities supported by the Commission] represents a strong platform for further 
strengthening the implementation of evidence-based policies’ – UNAIDS. 
Box 4.15: Systematic reviews and scientific papers 
EMCDDA has published analyses of trends in injecting drug use in Europe and of prevention policies and 
interventions (e.g. a monograph on evidence relating to harm reduction published in 201045
In 2009, ECDC published a systematic review of behavioural and psychological HIV and STI prevention 
interventions for MSM in Europe
,) as well as technical 
papers and scientific articles.  
46
special issue of Eurosurveillance
 which identified the characteristics of effective interventions as well as gaps in 
the evidence base. ECDC also published scientific papers on this topic in a  and 
hosted a seminar in the European Parliament to raise awareness on the high rates of HIV and STI transmission 
among MSM in Europe. A subsequent project in 2010–2011 further investigated HIV and STI trends among MSM 
and the effectiveness of prevention interventions. These projects will be used as a basis for developing an ECDC 
strategy for sexual health promotion and guidance on HIV and STI prevention among MSM in Europe.  
ECDC has published a series of migrant health reports that have made an important contribution to the evidence 
base for policy and programming and have been widely cited. Topics covered by these reports include improving 
definitions and data, the epidemiology of HIV and AIDS in migrant and ethnic minority communities, migrant 
access to HIV prevention, treatment and care services, and HIV counselling and testing among migrants and ethnic 
minorities. 
An ongoing ECDC project will inform the development of policy guidance on treatment as prevention that is 
relevant to the European context. Based on a review of the published scientific literature, the project will assess 
the implications of using antiretroviral treatment to prevent HIV infection at the population level, and to a lesser 
extent, at the individual level for prevention policies.  
 
EU agencies and EU-funded projects are an importance source of scientific and technical advice and play a key role 
in dissemination of learning. 
A range of methods is used to provide scientific advice and disseminate learning. 
Networks and scientific committees play a key role. Scientific advice has been strengthened by efforts to build 
networks. Principal investigators and coordinators of EU-funded research projects are represented in scientific 
committees that advise on research agendas, for example, the Global HIV Vaccine Enterprise 2010 agenda and the 
‘Towards an HIV Cure’ initiative. 
 
                                                                    
45 Harm reduction: Evidence, impacts and challenges. April 2010. EMCDDA, Lisbon. 
46 Effectiveness of behavioural and psychosocial HIV/STI prevention interventions for MSM in Europe. Technical report. 
Revised edition, December 2009. ECDC, Stockholm.  
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Think Tank and Civil Society Forum meetings have also provided an important forum for sharing and disseminating 
good practice, according to the majority of respondents who participate in these meetings. 
The regular meetings of the EU Civil Society Forum and Think Tank on HIV/AIDS represent exemplary 
models of best practice in convening fora where European civil society and governments can exchange 
information on the situation in EU and neighbouring countries and share experiences of joint projects 
and other activities – often supported by the EU public health programmes – UNAIDS 
AIDS Action Europe, which is funded by the Commission, disseminates information on best practices to a wide 
audience in Europe and Central Asia.  
Scientific advice has been consolidated by joint projects and efforts to facilitate the coordination of scientific 
research through multi-centre studies and a focus on evidence-based research. 
Scientific advice and technical support is provided to Member States by EU agencies, including through country 
visits. ECDC provides scientific advice and technical support on infectious diseases to the Commission, European 
Parliament, European-funded projects and Member States. During the period 2009–2011, ECDC improved systems 
for initiating and coordinating scientific studies and providing scientific advice. Specific examples of scientific advice 
to Member States include enhanced microbiological laboratory support and country visits in response to requests 
from national HIV/STI prevention and control programmes, to Estonia in 2010 and to Romania and Latvia in 2011. 
EMCDDA provides EU Member States with scientific advice and technical support on drug issues including the 
evaluation of national drug policies, HIV and drug-related studies and the development of monitoring systems. 
EMCDDA has also provided technical support to Candidate and potential Candidate Countries on drug monitoring 
systems and the collection of data on policies and interventions to prevent infectious diseases among drug users. 
‘The work of EU institutions, notably ECDC and EMCDDA, have enabled good access to scientific advice and 
exchange among Member States’ – UNAIDS. 
Scientific advice is also provided to other bodies. For example, at the EU level, EMCDDA provides technical advice 
to meetings of the Horizontal Working Party on Drugs and to EU Presidencies, and has evaluated the EU Drugs 
Action Plan 2009–2012 and provides advice on drug policy. 
ECDC and the Commission have disseminated policies, guidance and good practice on HIV prevention and 
treatment through events at the European Parliament. Similarly, the Parliament has been used as a forum to 
highlight the HIV prevention needs of MSM (2009), to launch the HIV testing guidance (2010) and to hold a 
seminar on HIV prevention among people who inject drugs (2011). 
Scientific advice and information on best policy and practice have also been disseminated through Commission-
funded and other international conferences. Commission-funded conferences include the European AIDS 
Conference in Tallinn in 2011 and the Future of European Prevention among MSM conference in Stockholm in 2011. 
The Tallinn conference facilitated the exchange of knowledge, experience, best practices and research findings in 
the field of HIV prevention, treatment and care, with a special focus on vulnerable groups and health systems in 
the Baltic region and ENP countries. The Stockholm conference focused on innovative and evidence-based methods 
and approaches to scaling up preventive interventions and programmes, as well as promoting networking and the 
exchange of information.  
‘The CSF, the Bordernet project and the Tallinn Conference influenced our testing and counselling policies’ – Civil 
society respondent, Austria. 
The XVIII International AIDS Conference and Harm Reduction International’s 21st International Conference, both 
of which took place in 2010, provided an opportunity to disseminate information on best practices and share 
experience. Moreover, at the latter the European Harm Reduction Network was launched. 
Another important channel for the presentation of findings is publication. The findings of Commission-funded 
research projects have been widely published in peer-reviewed literature and have influenced international 
guidelines and practice, as the examples above illustrate. EU agencies such as ECDC and EMCDDA have also 
provided important scientific advice through the publication of guidelines and technical reports. 
Information is also published online. For example, EMCDDA has established a European ’Best practice portal’ on 
drugs to provide policymakers, researchers and programme managers with information on effective prevention, 
treatment and harm reduction interventions, national and international standards and guidelines, and evaluated 
best practice. EMCDDA also launches its annual reports on drug use at the European Parliament.  
AIDS Action Europe maintains an online database www.hivaidsclearinghouse.eu which contains over 1 200 
resources and sends e-news updates to 850 subscribers, including information about the CSF. Downloads from the 
site increased from 33 000 in 2009 to 52 000 in 2010. The EU-funded AIDS & Mobility database was transferred to 
the AIDS Action Europe clearinghouse in 2010. The AIDS Action Europe website www.aidsactioneurope.org attracts 
an average of 1 300 visits a month, 70% from European countries and, since 2009, has also provided a platform 
for information exchange on HIV and drugs-related projects funded by the Commission. In addition, EAHC 
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convenes meetings for EU-funded projects to share information and experience. For example, sessions were 
organised at the most recent International AIDS Conference in 2010 and the 2011 European Conference on 
HIV/AIDS in Tallinn.  
’The clearing house of AIDS Action Europe has become a major source of information on HIV and AIDS 
strategies’ – Civil society respondent, Belgium. 
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5. Conclusions and recommendations 
This section summarises the main conclusions concerning action taken in response to the Communication and 
Action Plan. It highlights those areas where there has been good progress and those where action needs to be 
intensified. It then proposes a number of recommendations, intended to improve both the implementation of the 
Communication and Action Plan and the monitoring and future evaluation of the Plan. 
5.1 Progress 
While there is no specific funding for implementation of the Communication and Action Plan, analysis of available 
information suggests that the level of financial inputs to support the Communication and Action Plan annually is 
around EUR 27.1 million. Financing is provided through a range of mechanisms and instruments. These include the 
Global Fund, the ENPI and structural funds, the European Health Programme, Framework Programme research 
projects, agencies of the European Union and international organisations. However, information on the amount of 
funding provided is only available for some mechanisms and instruments and does not capture all financial inputs. 
The largest share of estimated total funding is allocated to research. This has contributed to the development of 
new treatments and prevention technologies, as well as to research to improve clinical management and patient 
outcomes. There is also evidence of active engagement with the private sector in the area of biomedical research. 
The next largest share is represented by funding for country responses in the region through the Global Fund, 
followed by resources allocated to the European Health Programme. The European Commission has provided 
significant funding for national responses to HIV in Europe through the Global Fund, with the largest amounts 
going to the Russian Federation and Ukraine. Funding for national responses to HIV is also available to priority 
regions through mechanisms including the ENPI and structural funds. 
Funding for the European Health Programme through EAHC has focused on populations most at risk of HIV, 
including men who have sex with men, people who inject drugs, sex workers, prisoners, migrants and ethnic 
minorities, with almost two-thirds of funds allocated to projects targeting these groups.  
Support provided in line with the priorities highlighted in the Communication and Action Plan has resulted in a 
strong focus on expanding targeted prevention services for populations most affected by HIV, including men who 
have sex with men, sex workers and people who inject drugs, as well as the provision of HIV-related services in 
prisons.  
Commission funding through the Global Fund has supported the scaling up of HIV-related services in the most 
affected Member States, neighbourhood countries and the Russian Federation. It is estimated that, through the 
Global Fund, the Commission has supported provision of harm reduction services to over 34 000 people who inject 
drugs and HIV prevention services to over 10 000 sex workers and their clients, over 13 000 men who have sex 
with men and over 25 000 prisoners. In addition, it has supported the provision of HIV counselling and testing 
services for almost two million people and antiretroviral therapy for over 6 000 people.  
Commission support has also contributed to the development of better approaches to service delivery to reach the 
most-at-risk and marginalised populations. The European Health Programme has supported projects that have 
tested new approaches to service delivery, such as innovative HIV counselling and testing approaches to increase 
access for vulnerable groups and promote earlier HIV diagnosis. The issue of HIV among migrant populations has 
received considerable attention, contributing to a better understanding of factors affecting migrant access to 
prevention, treatment and care services.  
The Communication is an important tool for galvanising political leadership. It has helped to ensure that HIV 
remains on the agenda and has been used by civil society to frame debate at regional and national levels. The 
Think Tank and the Civil Society Forum are valuable platforms for policy dialogue and exchange of information and 
experience, as well as for promoting Europe-wide action and effective communication between the Commission, 
Member States, EEA and Candidate Countries, priority ENP countries and the Russian Federation, civil society and 
international agencies.  
Commission financing for international organisations, international and regional conferences and monitoring the 
implementation of international and regional commitments has helped to keep HIV on the agenda in Europe and to 
mobilise political leadership in the region, especially in those countries most affected by the epidemic. Collaboration 
with international agencies such as UNAIDS and WHO has also helped to ensure common approaches and to 
facilitate regional responses that reflect epidemic priorities. 
Civil society involvement has been supported through funding to build the capacity of non-state actors in ENP 
countries and through Commission support for and engagement with the Civil Society Forum, which plays a critical 
role in facilitating dialogue between civil society and policy makers. Participation in the Civil Society Forum has 
enabled civil society organisations to play a more visible role in national policy dialogue in a number of countries. 
 
 
 
 
SPECIAL REPORT Monitoring implementation of the Commission Communication and Action Plan on HIV/AIDS 
 
 
 
41 
 
 
 
Funding for agencies such as ECDC and EMCDDA has emphasised improving knowledge, focusing in particular on 
epidemiological and behavioural surveillance, monitoring and evaluation, and the evidence base for policy and 
programming. Specific efforts by EMCDDA, ECDC and projects funded by the European Health Programme have 
contributed to a better understanding of the impact of the HIV epidemic among those population groups most 
affected in the region, in particular people who inject drugs, men who have sex with men, and migrants from high 
prevalence countries.  
Support for ECDC has resulted in significant improvements in HIV-related epidemiological surveillance in the region, 
especially in the comprehensiveness, quality and dissemination of HIV surveillance data. There has also been 
progress in strengthening surveillance systems to monitor HIV and TB co-infection. In addition, Commission 
support has given high priority to strengthening regional cooperation, in particular to ensure coordinated 
approaches to surveillance, monitoring and reporting of data.  
HIV monitoring and reporting have also improved. ECDC efforts have significantly enhanced reporting rates by 
countries in the region, both on implementation of the Dublin Declaration and on UNGASS indicators. Progress has 
been made towards developing a set of regionally specific and harmonised indicators, which will further improve 
monitoring of the HIV response in Europe and is expected to reduce the reporting burden. 
The Commission has also supported efforts to ensure that policy and programming are based on sound research 
and evidence. Clinical and operational research is generating important evidence on issues such as the cost-
effectiveness of screening strategies for HIV and hepatitis, the clinical management of HIV, and the control of HIV 
drug resistance. Systematic reviews and evidence papers have informed the development of guidance on 
approaches to HIV prevention among men who have sex with men and people who inject drugs as well as up-to-
date guidance on HIV testing and the potential to use HIV treatment as a prevention strategy.  
High priority has been given to sharing scientific and clinical expertise. EU agencies and initiatives financed by the 
Commission are valuable sources of scientific and technical advice to countries. Evidence, guidance and best 
practices are also disseminated through the European Parliament, scientific networks and committees, international 
and regional conferences, policy, technical and scientific publications, databases and clearing houses.  
5.2 Challenges 
However, there are areas of the Communication and Action Plan that have received less attention or where it is 
more difficult to identify effects (see Annex 1).  
Better information is needed about country use of mechanisms such as the ENPI and structural funds to fund 
national responses to HIV. There are also concerns about whether some countries that have been receiving 
funding from the Global Fund will be committed or able to sustain HIV prevention and treatment, once Global Fund 
support ends. Sustaining HIV programmes requires stronger political leadership from the Commission as well as 
from national authorities. 
In addition, while European support has made an important contribution to improving both the coverage and the 
quality of services, more needs to be done to achieve universal access. In particular, it is vital to ensure adequate 
provision of harm reduction, HIV and TB co-infection services and services for specific population groups, including 
men who have sex with men, prisoners and migrants. 
The balance of research funding does not fully reflect the priorities identified in the Action Plan. Research funding 
has largely been allocated to biomedical research. While this makes sense, as regional research initiatives have 
inherent comparative advantages, less funding has been provided for social and behavioural research and socio-
economic analysis. In addition, considerable support has been provided to strengthen research capacity, 
networking and collaboration, but the effects are difficult to assess as little evidence is available on the outcomes 
of this support. 
There is scope to improve political leadership in order to ensure that HIV continues to be given sufficient priority in 
the region as well as in European development financing. The potential for EU Presidencies to provide political 
leadership has not been exploited to the full. Since the adoption of the Communication, only the Spanish 
Presidency has provided leadership on HIV by hosting an official Presidency meeting. National AIDS coordinators 
have not met during the period under review. Separate meetings are not considered necessary as other forums, 
such as the Think Tank, provide opportunities for dialogue. 
There is a need to intensify policy dialogue with ENP countries, through existing mechanisms such as Commission 
Delegations, cooperation agreements and memoranda of understanding, meetings and exchange programmes, to 
increase political leadership and ensure that the health and rights of vulnerable and marginalised groups are 
addressed.  
Support has been provided to civil society organisations, but there are concerns about the reduced availability of 
funding for NGOs in a number of countries and the impact of the economic downturn on future funding for civil 
society. Sustained support is critical if civil society is to continue to contribute to national responses. In addition, it 
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is unclear to what extent support has been provided to promote the involvement of people living with HIV or of 
those population groups most affected by HIV. 
There appears to have been limited action to monitor national HIV policies and specific policies and laws 
concerning HIV-related discrimination. More needs to be done to ensure that appropriate legislative and policy 
frameworks are in place and to tackle discrimination in relation to both people living with HIV and marginalised 
population groups.  
Commission engagement with the private sector appears to have had limited impact on antiretroviral pricing and 
treatment coverage or the coverage of HIV-related workplace programmes. Progress in discussions with the 
pharmaceutical industry about improved access to and availability of antiretroviral treatment across Europe will 
require increased commitment by Member States.  
While efforts are being made to improve and harmonise behavioural surveillance, more needs to be done to 
strengthen second generation surveillance and to support enhanced surveillance in EU/EEA Member States, and in 
particular in ENP countries and the Russian Federation.  
Finally, it is difficult to measure the impact of efforts to strengthen the evidence base, promote sharing of 
experience and disseminate guidance (particularly at the national policy and programming level) as there appears 
to be little systematic follow up of these activities.  
5.3 Recommendations 
To improve implementation of the Communication and Action Plan: 
• Strengthen political leadership on critical issues. Specifically: 
o The European Commission and Member States should intensify action to ensure that national 
responses to HIV are adequately financed, including funding for civil society organisations. 
o The European Commission should take the lead in initiating dialogue on how countries can sustain 
HIV prevention programmes as well as HIV treatment and care services in the context of the current 
economic downturn and declining support from the Global Fund.  
o The European Commission, Think Tank and Civil Society Forum should intensify efforts to ensure that 
EU Presidencies give high priority to HIV and provide effective leadership. One option would be to 
explore the possibility of organising a high-level meeting on HIV in cooperation with one of the EU 
Presidencies before the end of the current Communication Plan in 2013, similar to the one organised 
in Dublin 2004 during the Irish EU Presidency. 
o The European Commission should develop and implement a strategy for engagement with the private 
sector, including the promotion of increased commitment by EU Member States to the dialogue on 
affordable antiretroviral drugs. 
• Make better use of the range of mechanisms and instruments available to address the needs of priority 
groups in priority regions. Specifically: 
o The European Commission should make better use of policy dialogue, including mechanisms such as 
cooperation agreements, exchange programmes and meetings, to promote more effective political 
leadership in the most affected Member States, ENP countries and the Russian Federation, in 
particular with respect to services for priority populations. 
o The European Commission should ensure that its funding through the European Health Programme 
and other mechanisms targets those populations most-at-risk, with resource allocation clearly based 
on the epidemiology of the epidemic. 
o The European Commission should review the potential to use ENPI and structural funds to 
complement national financing of country responses that prioritise targeted prevention services and 
improve treatment coverage for priority groups. This analysis will need to be conducted in partnership 
with beneficiary countries, which are expected to provide matching funds. 
• Build on progress to date to ensure access to prevention, treatment and care and to protect the rights of 
people living with and affected by HIV. Specifically: 
o The European Commission and civil society should sustain advocacy and support for universal access 
to prevention, treatment and care, expansion of harm reduction services, including NSP and 
substitution treatment programmes, and integration of HIV and TB services in EU Member States, 
ENP countries and the Russian Federation. 
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o The European Commission, Member States and civil society should sustain efforts to step up effective 
HIV prevention strategies for men who have sex with men.  
o The European Commission, Member States and civil society should ensure that analytical work on the 
situation of migrant populations is translated into policies and programmes to ensure that both 
documented and undocumented migrants can access HIV prevention, treatment and care services.  
o The European Commission and ECDC should monitor policy development and implementation. 
o The European Commission, Member States and civil society should intensify efforts to tackle 
discrimination, including the enactment of anti-discrimination laws and the monitoring of 
discrimination in relation to HIV status. 
• Strengthen research and surveillance. Specifically: 
o The European Commission should take steps to ensure a more balanced allocation of funding for 
research, by increasing resources for social, behavioural and economic research and stimulating 
research in these areas. 
o The European Commission, ECDC, EMCDDA, academic institutions and civil society should intensify 
support for improved behavioural surveillance and analysis of risk behaviour. 
o ECDC should increase cooperation with ENP countries and the Russian Federation to strengthen 
surveillance in these countries.  
To improve monitoring and evaluation of the Communication and Action Plan:  
• Improve the quality of information available about financial and non-financial inputs to support 
implementation of the Communication and Action Plan. Specifically: 
o Maintain accurate data on financing provided by the Commission through different mechanisms and 
instruments to allow financial inputs to be fully captured. 
Maintain accurate data on HIV-related activities undertaken through Commission Delegations, 
cooperation agreements, meetings and exchange visits. 
o Monitor the quality and impact of projects and other activities funded. 
• Give higher priority to monitoring and evaluation of activities financed by the Commission. Specifically: 
o Ensure that Commission-funded programmes and projects include an evaluation component and 
measure whether or not the desired effects have been achieved. 
o Take a systematic approach to monitoring the impact of actions taken to promote political leadership 
and strengthen networking and collaboration. 
o Monitor the impact of scientific and technical advice and dissemination of evidence, guidance and 
best practices on national policy and programmes. 
• Review the relevance of actions to be monitored and methods used to solicit information. Specifically: 
o Consider whether it is necessary to continue with, and hence to monitor, some actions. 
o Consider whether more use could be made of Think Tank and Civil Society Forum meetings to solicit 
information. 
o Identify additional methods to solicit information required for monitoring and evaluation of the 
Communication and Action Plan. 
5.4 Next steps 
ECDC will continue to monitor the implementation of the Communication and Action Plan. This process will again use 
tailored questionnaires to solicit information from key actors and implementing partners, as well as using other methods 
to enhance the quality of data. 
A final report on the implementation of the Communication and Action Plan will be published in 2013. This will also 
include data collected on country actions and impacts during the monitoring of the Dublin Declaration, which will allow 
further analysis of the extent to which Commission support is aligned with country needs and priorities.   
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Annex 1: Areas of the Action Plan where 
intensified action is required 
Actions  Responsible Comments  
Promote HIV as a public health and social 
concern, keep it on the political agenda. 
Commission, Member States, neighbouring 
countries, civil society, international 
organisations 
Good progress through Think Tank, Civil 
Society Forum, international and regional 
conferences and organisations. More could 
be done by Commission, EU Presidencies 
and with neighbouring countries. 
Tackle discrimination related to HIV 
status. 
Commission, Member States and 
neighbouring countries, civil society 
Limited evidence of action or effects. More 
needs to be done to ensure laws and 
policies are implemented and monitored. 
Develop, implement, monitor and evaluate 
targeted, regional, national and 
supranational HIV/AIDS policies. 
Member States, civil society, ECDC, 
international organisations 
Limited evidence of concerted action to 
review policy development/implementation 
or to evaluate policies. 
Support civil society through funding and 
legal support at EU and national level. 
Involve and consult civil society in HIV 
policy development and implementation. 
National authorities, Commission Support for civil society needs to be 
sustained, including by Member States, in 
light of reduced Global Fund support and 
economic crisis.  
Intensify cooperation with the private 
sector – business and media. Work with 
the pharmaceutical industry to improve 
access and availability of treatment across 
Europe. 
Industry, national authorities, Commission, 
civil society 
Commitment in the area of biomedical 
research. More needs to be done to 
engage Member States in dialogue with 
the pharmaceutical industry on HIV drug 
pricing.  
Strengthen behavioural surveillance to 
develop measures leading to reduced risk 
behaviour. In-depth analysis of trends and 
dynamics in sexual and drug-related risk 
behaviour. 
ECDC, EMCDDA, academia, Commission, 
civil society 
Initial steps taken to improve behavioural 
surveillance, but efforts need to be 
stepped up. 
Eastern European countries, ENP countries 
and Russian Federation: obtain universal 
access to voluntary testing, treatment and 
care. Introduce and implement effective 
harm reduction measures for HIV 
prevention. Prevention and integrated 
HIV, TB and co-infection treatment, in 
prisons and other settings. 
National authorities, civil society, 
Commission 
Good progress, but more needs to be 
done to achieve universal access and 
acceptable coverage. 
ENP countries and Russian Federation: 
promote cooperation of EU and 
neighbouring countries on HIV/AIDS. 
Involvement of neighbouring countries in 
HIV-related meetings at EU level. 
Commission, Member States, ENP 
countries 
Scope to strengthen cooperation through 
existing mechanisms and instruments. 
ENP countries and Russian Federation: 
Strengthen surveillance by stepping up 
cooperation between ECDC and ENP 
institutions. 
ECDC, surveillance institutions Although strides have been made, there is 
scope to strengthen cooperation. 
Exchange programmes between Member 
States and neighbouring countries. 
Medical associations, industry, Member 
States, neighbouring countries, civil 
society 
Scope to make better use of exchange 
programmes. 
Intensify promotion of safer sex behaviour 
among MSM.  
Civil society, Member States, neighbouring 
countries, Commission, ECDC 
Good progress, but more needs to be 
done as risk taking behaviour in MSM is 
increasing, along with the number of HIV 
infections and other STIs. 
Intensify VCT (Voluntary Counselling and 
Testing) and outreach for MARPs (Most At 
Risk Populations) 
Civil society, Member States, neighbouring 
countries, medical associations, 
Commission 
Good progress, but more needs to be 
done to build on this. 
Implement harm reduction for prevention 
of HIV and drug-dependency 
Member States, neighbouring countries, 
civil society, Commission 
Good progress, but more needs to be 
done to build on this. 
Targeted prevention measures and access 
to services and treatment for migrants 
Migrant and ethnic minority organisations, 
national authorities, Commission, civil 
society 
Important analysis carried out. More needs 
to be done to develop related policies and 
programmes. 
Social, and behavioural research and 
socio-economic analysis. 
ECDC, academia, Commission. Member 
States, civil society. 
Limited funding. Greater efforts needed to 
stimulate research on these aspects of the 
epidemic in Europe. 
 
